<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2707222353
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VENCLEXTA 10 mg / 50 mg / 100 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VENETOCLAX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10, 50, 100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        42
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6695.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ABBVIE IRELAND NL B.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ABBVIE IRELAND NL B.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBVIE Inc.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX52
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VENCLEXTA contains the active substance venetoclax. It belongs to a group of medicines called &ldquo;BCL-2 inhibitors&rdquo;.</p><p><strong>What VENCLEXTA is used for</strong></p><p>VENCLEXTA is a prescription medicine used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat adults with Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newlydiagnosed acute myeloid leukemia (AML) who:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are 75 years of age or older, <strong>or</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have other medical conditions that prevent the use of standard chemotherapy</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>It is not known if VENCLEXTA is safe and effective in children.</p><p><strong>How VENCLEXTA works&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>VENCLEXTA works by blocking a protein in the body called &ldquo;BCL-2&rdquo;. This is a protein that helps cancer cells survive. Blocking this protein helps to kill and lower the number of cancer cells. It also slows down the worsening of the disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Before taking VENCLEXTA, tell your doctor about all of your medical conditions, including if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney or liver problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of high uric acid levels in your blood or gout</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are scheduled to receive a vaccine. You should not receive a &ldquo;live vaccine&rdquo; before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby. If you are able to become pregnant, your doctor should do a pregnancy test before you start treatment with VENCLEXTA. Females who are able to become pregnant should use effective birth control during treatment and for at least 30 days after the last dose of VENCLEXTA.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you become pregnant or think you are pregnant, tell your healthcare provider right away.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; <strong>b. Do not take VENCLEXTA if:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to the active substance venclexta or any of the other ingredients of this medicine (listed in section 7).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking any of the medicines listed below when you start your treatment and while your dose is gradually being increased (usually over 5 weeks). This is because serious and life-threatening effects can occur when venclexta is taken with these medicines:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole, ketoconazole, posaconazole, or voriconazole for fungal infections</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clarithromycin for bacterial infections</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir for HIV infection.</p><p>When your venclexta dose has been increased to the full standard dose, check with your doctor if you can start taking these medicines again.</p><p>&nbsp;&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking a herbal medicine called St. John&rsquo;s wort, used for depression. If you are not sure about this, talk to your doctor, pharmacist or nurse before taking venclexta&rdquo;</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; c</strong><strong>. Taking other medicines, herbal or dietary supplements</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your </strong>healthcare provider <strong>about all the medicines you take,</strong> including prescription and over-the-counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.</p><p>&nbsp;</p><p>Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.</p><p><strong>d. Taking VENCLEXTA with food and drink</strong></p><p>You should not drink grapefruit juice, eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.</p><p><strong>e</strong><strong>. Pregnancy and breast-feeding</strong></p><p><u>Pregnancy</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not get pregnant while you are taking this medicine. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before taking this medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; VENCLEXTA should not be used during pregnancy. There is no information about the safety of venetoclax in pregnant women.</p><p><u>Contraception</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women of childbearing age must use a highly effective method of birth control during treatment and for up to one month after receiving VENCLEXTA to avoid becoming pregnant. If you are using hormonal contraceptive pills or devices, you must also use a barrier method of contraception (such as condoms).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor immediately if you become pregnant while you are taking this medicine.</p><p><strong>&nbsp;</strong></p><p><u>Breast-feeding</u></p><p>Do not breast-feed while you are taking this medicine</p><p><u>Fertility</u></p><p>VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.</p><p>&nbsp;</p><p><strong>f</strong><strong>. Driving and using machines</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>It is not known if VENCLEXTA affects the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How should I take VENCLEXTA?</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Take VENCLEXTA exactly as your healthcare provider tells you to take it. Do not change your dose of VENCLEXTA or stop taking VENCLEXTA unless your healthcare provider tells you to.</p><p>&bull;&nbsp;&nbsp;&nbsp; When you first take VENCLEXTA:</p><p>◦&nbsp;&nbsp;&nbsp; You may need to take VENCLEXTA at a hospital or clinic to be monitored for TLS.</p><p>◦&nbsp;&nbsp;&nbsp; If you are taking VENCLEXTA for CLL or SLL, your healthcare provider will start VENCLEXTA at a low dose. Your dose will be slowly increased weekly over 5 weeks up to the full dose. Read the Quick Start Guide that comes with VENCLEXTA before your first dose.</p><p>◦&nbsp;&nbsp; If you are taking VENCLEXTA for AML, your healthcare provider will start VENCLEXTA at a lowdose. Your dose will be slowly increased daily up to the full dose. Follow your healthcare provider&rsquo;s instructions carefully while increasing to the full dose.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Follow the instructions about drinking water described in the section of this PIL about TLS called <strong>&ldquo;Serious Side Effects&rdquo;</strong> and also in the Quick Start Guide.</p><p>&bull;&nbsp;&nbsp;&nbsp; Take VENCLEXTA 1 time a day with a meal and water at about the same time each day.</p><p>&bull;&nbsp;&nbsp;&nbsp; Swallow VENCLEXTA tablets whole. Do not chew, crush, or break the tablets.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you miss a dose of VENCLEXTA and it has been less than 8&nbsp;hours, take your dose as soon as possible. If you miss a dose of VENCLEXTA and it has been more than 8 hours, skip the missed dose and take the next dose at your usual time.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you vomit after taking VENCLEXTA, do not take an extra dose. Take the next dose at your usual time the next day.</p><p>&nbsp;</p><p>Keep VENCLEXTA tablets in the original package during the first 4 weeks of treatment. <strong>Do not</strong> transfer the tablets to a pillbox or other container.</p><p>&nbsp;</p><p><strong>a</strong><strong>. If you take more VENCLEXTA than you should</strong></p><p>&nbsp;</p><p>If you take more VENCLEXTA than you should, talk to your healthcare provider or go to hospital immediately. Take the tablets and this leaflet with you.</p><p><strong>b. If you forget to take VENCLEXTA</strong></p><ul><li>If it is less than 8 hours since the time you usually take your dose, take it as soon as possible.</li><li>If it is more than 8 hours since the time you usually take your dose, do not take the dose that day. Return to your normal dose schedule the next day.</li><li>Do not take a double dose to make up for a forgotten dose.</li><li>If you are not sure talk to your doctor, pharmacist or nurse.</li></ul><p>&nbsp;</p><p><strong>c</strong><strong>. Do not stop taking VENCLEXTA</strong></p><p>Do not stop taking this medicine unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p><p>If you have any further questions on the use of this product, ask your doctor, healthcare provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VENCLEXTA can cause serious side effects, including:</p><ul><li><strong>Low white blood cell count (neutropenia).</strong> Low white blood cell counts are common with VENCLEXTA, but can also be severe. Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA.</li><li><strong>Infections</strong>. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you have fever or any signs of infection during treatment with VENCLEXTA.</li></ul><p>&nbsp;</p><p>Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.</p><p>&nbsp;</p><p>The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include:with CLL include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low platelet counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle and joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your arms, legs, hands, and feet</p><p>&nbsp;</p><p>&nbsp;</p><p>The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or lowdose cytarabine in people with AML include:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;low platelet counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever with low white blood cell counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;low red blood cell counts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection in blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your arms, legs, hands, and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection in lung</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach (abdominal) pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in muscles or back</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;sore throat</p><p>&nbsp;</p><p>VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to</p><p>your healthcare provider if you have concerns about fertility.</p><p>These are not all the possible side effects of VENCLEXTA. For more information, ask your healthcare</p><p>provider or pharmacist.</p><p>&nbsp;</p><p>Call your doctor for medical advice about side effects</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children</p><p>&bull;&nbsp;&nbsp;&nbsp; Store VENCLEXTA at or below 86&deg;F (30&deg;C).</p><p>&bull;&nbsp;&nbsp;&nbsp; For people with CLL/SLL, keep VENCLEXTA tablets in the original package during the first 4 weeks of treatment. <strong>Do not</strong> transfer the tablets to a different container.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Active ingredient: </strong>venetoclax</p><p><strong>Inactive ingredients:</strong> copovidone, colloidal silicon dioxide, polysorbate 80, sodium stearyl fumarate, and calcium phosphate dibasic.</p><p>The 10 mg and 100 mg coated tablets also include: iron oxide yellow, polyvinyl alcohol, polyethylene glycol, talc and titanium dioxide. The 50 mg coated tablets also include: iron oxide yellow, iron oxide red, iron oxide black, polyvinvyl alcohol, talc, polyethylene glycol, and titanium dioxide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VENCLEXTA 10 mg film-coated tablets are round, biconvex shaped, pale yellow debossed with “V” on one side and “10” on the other side.

VENCLEXTA 50 mg film-coated tablets are oblong, biconvex shaped, beige debossed with “V” on one side and “50” on the other side.
 
VENCLEXTA 100 mg film-coated tablets are oblong, biconvex shaped, pale yellow tablet debossed with “V” on one side and “100” on the other side.

Packaging Presentation	Number of Tablets
Starting Pack	Each pack contains four weekly wallet blister packs:
•	Week 1 (14 x 10mg tablets)
•	Week 2 (7 x 50mg tablets)
•	Week 3 (7 x 100mg tablets)
•	Week 4 (14 x 100mg tablets)
10mg Wallet	14 x 10mg tablets
50mg Wallet	7 x 50mg tablets
10mg Unit Dose	2 x 10mg tablets
50mg Unit Dose	1 x 50mg tablet
100mg Unit Dose	1 x 100mg tablet
100mg Bottle	120 x 100mg tablets
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AbbVie Inc</p><p>North Chicago</p><p>IL 60064</p><p>Chicago</p><p>United States</p><p><strong>Manufactured by:</strong></p><p>AbbVie Ireland NL B.V.</p><p>Manorhamilton Road</p><p>Sligo, Ireland</p><p><strong>Packaged by:</strong></p><p>AbbVie Inc1 N Waukegan Rd. North Chicago, IL 60664 USA<em>&nbsp; </em></p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</p><p>&nbsp;</p><p><strong><u>Abbvie Biopharmaceuticals GmbH </u></strong></p><p>Hot line: 00966 55 828 2010</p><p>Mailbox: Pv.Saudiarabia@abbvie.com</p><p>&nbsp;</p><p>d. This leaflet was last approved in <em>July 2019</em></p><p>&nbsp;</p><p>e. To report any side effect(s):</p><p>&nbsp;</p><p><strong><u>Saudi Arabia</u></strong></p><p>The National Pharmacovigilance and Drug Safety Center - Saudi food and drug authority<s>:</s></p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222,</p><p>Ext: <s>-</s>2317-2356-2353-2354-2334</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc<u>&nbsp;</u></p><p><img alt="" width="597" height="67" src="data:image/png;base64,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" /></p><p><img alt="" width="604" height="395" src="data:image/png;base64,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" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in July 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يتضمّن دواء فينكليكستا المادة النشطة فينيتوكلاكس وهي تنتمي إلى مجموعة أدوية تُسمى &quot;مثبطات ليمفوما خلايا بيتا المناعيّة&quot;.</p><p dir="RTL"><strong>لماذا يُستعمل </strong><strong>دواء فينكليكستا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">فينكليكستا دواء يؤخذ بموجب وصفة طبية ويُستعمل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الأشخاص البالغين الذين يعانون من سرطان الدم الليمفاوي المزمن أو ليمفوما الخلايا الليمفاوية الصغيرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالاشتراك مع آزاكتيدين، أو ديسيتابين، أو جرعة منخفضة من سيتارابين لعلاج البالغين الذين شخصّت لديهم حديثا الإصابة بسرطان الدم النقوي الحادّ الذين:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بلغ عمرهم 75 سنة أو أكثر، أو</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعانون من حالات مرضية أخرى تمنع استعمال العلاج الكيمياوي القياسي</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف بعد ما إذا كان فينكليكستا آمناً وفعّالاً للأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل دواء فينكليكستا</strong></p><p dir="RTL">يعمل فينكليكستا على استهداف بروتيين BCL-2 &quot; ليمفوما خلايا بيتا المناعيّة&quot;، الذي يلعب دوراً حيوياً في نمو الخلايا السرطانية. من هنا، فإنّ استهداف هذا البروتين يساعد على قتل الخلايا السرطانية وتقليل عددها، كما أنه يبطئ تدهور الحالة المرضية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قبل أن تتناول فينكليكستا، أطلع طبيبك على كافة ظروفك الصحية والطبية بما في ذلك إذا كنت:</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تعاني مشاكل كلى أو الكبد</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تعاني مشاكل في أملاح أو كهارل الجسم على غرار البوتاسيوم أو الفسفور أو الكلسيوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك سجل في التعرض لمستويات عالية من حمض اليوريك في الدم أو التهاب المفاصل (النقرس)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك موعد لتلقي لقاح ما. لا يجب أن تتلقى &quot;لقاحًا حيًا&quot; قبل العلاج بفينكليكستا وبعده وخلاله إلى أن يقول لك مقدّم الرعاية الصحيّة أنه بإمكانك تلقي اللقاح. إذا لم تكن متأكدًا من نوع اللقاح الذي ستتلقاه، سل مقدّم الرعاية الصحيّة ، فهذه اللقاحات قد لا تكون آمنة أو فعالة خلال العلاح بفينكليكستا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت امرأة حامل أو تخططين للحمل لأنّ فينكليكستا يضرّ بالمولود الذي لم يولد بعد. إذا كنت قادرة على الحمل، يجري الطبيب اختبار الحمل قبل البد بعلاج فينكليكستا. يتوجّب على المرأة القادرة على الحمل أن تستخدم وسيلة منع حمل فعالة خلال العلاج وبعد آخر جرعة بثلاثين يومًا على الأقلّ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حملت أم شككت بأنك حامل، اخبري مقدّم الرعاية الصحيّة على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت امرأة مرضعة أو تخطط للارضاع. ليس معلومًا ما إذا كان فينكليكستا ينتقل في حليب الرضاعة، لا ترضعي طفلك وأنت تتناولين هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب- </strong><strong>لا تتناول فينكليكستا إذا كنت:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من حساسية تجاه المادة الفعالة في فينكليكستا أو<strong> </strong>أي من مكوّنات هذا الدواء الأخرى (المذكورة في القسم 7).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أيا من الأدوية المذكورة أدناه عندما تبدأ علاجك وأثناء الزيادة التدريجية لجرعتك (على مدى 5<strong> </strong>أسابيع عادة). ويرجع هذا لامكانية حدوث تأثيرات جانبية خطيرة ومهددة للحياة عند تناول فينكليكستا مع هذه الأدوية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إتراكونازول، كيتوكونازول، بوساكونازول، أو فوريكونازول لعلاج حالات العدوى الفطرية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلاريثررومايسين لعلاج حالات العدوى البكتيرية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير لعلاج حالات العدوى بفيروس العوز المناعي البشري</p><p dir="RTL">عندما تصل جرعتك من فينكليكستا إلى الجرعة القياسية القصوى، إسأل مقدّم الرعاية الصحيّة إذا كان بإمكانك أن تبدأ بتناول هذه الأدوية من جديد.</p><ul><li dir="RTL">تتناول دواء عشبيا اسمه عشبة سانت جونز الذي يستعمل في علاج الاكتئاب. إذا لم تكن متأكدا من الأمر، فاستشر مقدّم الرعاية الصحيّة، الصيدلاني أو الممرضة قبل أن تبدأ بتناول فينكليكستا.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تناول أدوية أخرى أو مكملات عشبية أو غذائية</strong></p><ul><li dir="RTL"><strong>هناك بعض الأدوية التي يجب عدم تناولها عندما تبدأ بتناول </strong><strong>فينكليكستا وعندما تزداد جرعتك ببطء.</strong></li></ul><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أطلع </strong><strong>مقدّم الرعاية الصحيّة</strong><strong> على كافة الأدوية التي تتناولها</strong> بما فيها الأدوية والفيتامينات والمكمّلات العشبية التي تحتاج وتلك التي لا تحتاج إلى وصفة طبية. فقد يؤثر فينكليكستا وأدوية أخرى على بعضها ما يؤدي إلى عوارض جانبية خطيرة.</p><p dir="RTL">لا تبدأ بتناول أدوية جديدة خلال العلاج بفينكليكستا من دون استشارة مقدّم الرعاية الصحيّة أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تناول </strong><strong>فينكليكستا مع الأطعمة والشراب</strong></p><p dir="RTL">يجب ألا تتناول فاكهة الكريب فروت أو النارنج (المُستخدمة عادةً في المربيات) أو القلنباق ولا أن تشرب عصيرها خلال تناول فينكليكستا، فهي قد تزيد من كمية فينكليكستا في جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ه&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحملي وأنت تتناولين هذا الدواء. أما إذا كنت حاملاً أو تشكين بذلك أو تخططين للإنجاب، استشيري طبيبك أو الصيدلاني أو الممرض قبل تناول هذا الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي تناول فينكليكستا خلال الحمل. ليس هناك معلومات عن سلامة تواجد فينيتوكلاكس لدى المرأة الحامل.</p><p dir="RTL"><u>منع الحمل</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تستخدم المرأة في سنّ الإنجاب وسيلة منع حمل فعالة جدًا خلال العلاج وبعد تناول فينكليكستا بشهر لتفادي الحمل. إذا كنت تستخدمين وسيلة حمل قائمة على الهرمونات كحبوب أو أجهزة منع الحمل يجب استخدام طريقة الحاجز (مثل الواقي الذكري) في الوقت نفسه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أطلعي مقدّم الرعاية الصحيّة فورًا في حال حملت وأنت تتناولين هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة</u></p><p dir="RTL">لا ترضعي طفلك وأنت تتناولين هذا الدواء.</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">قد يتسبب دواء فينكليكستا بمشاكل خصوبة لدى الرجال ما قد يؤثر على قدرتك لتكون أبًا. تحدث إلى مقدّم الرعاية الصحيّة إذا كان لديك هواجس من حيث الخصوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس معلومًا ما إذا كان فينكليكستا يؤثر على القدرة على القيادة أو استخدام الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يجب أن أتناول فينكليكستا؟</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تناول هذا الدواء تمامًا كما يصفه مقدّم الرعاية الصحيّة، لا تغيّر الجرعات أو تتوقف عن تناوله ما لم يطلب منك مقدّم الرعاية الصحيّة ذلك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; عندما تتناول فينكليكستا لأول مرة:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحتاج إلى تناوله في المستشفى أو عيادة لكي تراقب خشية حدوث متلازمة انحلال الورم.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى فينكليكستا لعلاج سرطان الدم الليمفاوي المزمن أو ليمفوما الخلايا الليمفاوية الصغيرة، سيبدأ مقدّم الرعاية الصحيّة بإعطائك فينكليكستا بجرعة صغيرة وسيتم زيادتها ببطء أسبوعيًا على مدى 5 أسابيع إلى أن تصل إلى الجرعة الكاملة. اقرأ دليل البدء السريع الذي يأتي مع دواء فينكليكستا قبل تناول الجرعة الأولى.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى فينكليكستا لعلاج سرطان الدم النقوي الحادّ، سيبدأ مقدّم الرعاية الصحيّة بإعطائك فينكليكستا بجرعة صغيرة وسيتم زيادتها ببطء يوميا إلى أن تصل إلى الجرعة الكاملة. اتبع تعليمات مقدّم الرعاية الصحيّة بعناية بينما يزيد جرعتك لتصل إلى الجرعة الكاملة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; اتبع التعليمات حول شرب الماء الواردة في القسم المتعلق بمتلازمة انحلال الورم في هذه النشرة والمعنو<strong>ن &quot;الأعراض الجانبية الخطرة&quot;</strong> وفي دليل البدء السريع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تناول فينكليكستا مرةً في اليوم مع تناول الطعام والماء في الوقت نفسه من النهار تقريبًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ابتلع قرص فينكليكستا كلّه، لا تمضغه أو تكسره.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا فوّت جرعةً من فينكليكستا ومرّ عليها أقل من 8 ساعات، تناول جرعتك بأسرع وقت ممكن. أما إذا مضى أكثر من 8 ساعات ففوّت هذه الجرعة وتناول الجرعة التالية في الوقت المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا تقيّأت بعد تناول فينكليكستا لا تتناول جرعة إضافية. تناول الجرعة التالية في اليوم التالي وفي الوقت المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اترك أقراص فينكليكستا في علبتها الأصلية خلال الأسابيع الأربعة الأولى من العلاج. <strong>لا تضع</strong> الأقراص في علبة دواء أو أي علبة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>في حال تناولت جرعة من فينكليكستا أكثر من اللازم</strong></p><p dir="RTL">في حال تناولت جرعة من فينكليكستا أكثر من اللازم، استشر مقدّم الرعاية الصحيّة أو توجّه مباشرةً إلى المستشفى. خذ الأقراص وهذه النشرة معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp; </strong><strong>إذا نسيت تناول </strong><strong>فينكليكستا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فوّت جرعةً من فينكليكستا ومرّ عليها أقل من 8 ساعات، تناول جرعتك بأسرع وقت ممكن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا مضى أكثر من 8 ساعات لا تتناول جرعة هذا اليوم بل تناول الجرعة في اليوم التالي في الوقت المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعتين لتعوّض عن جرعة نسيتها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال التردد، استشر طبيبك أو الصيدلاني أو الممرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ت&zwnj;.&nbsp;&nbsp;&nbsp; </strong><strong>لا تتوقف عن تناول فينكليكستا</strong></p><p dir="RTL">لا تتوقف عن تناول هذا الدواء ما لم يطلب منك طبيبك ذلك، وإن كان لديك أي اسئلة إضافية حول استخدام هذا الدواء، استشر طبيبك أو الصيدلاني أو الممرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي اسئلة إضافية حول استخدام هذا المنتج، اطرحها على طبيبك أو مقدم الرعاية الصحية أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن لفينكليكستا أن يتسبّب بأعراض جانبية خطرة، من بينها:</p><ul><li dir="RTL">انخفاض عدد كريات الدم البيضاء (نقص الخلايا المعتدلة). من الشائع الإصابة بانخفاض عدد كريات الدم البيضاء لدى تناول فينكليكستا ولكن يمكن أن تصبح الحالة شديدة. يجري مقدّم الرعاية الصحيّة &nbsp;فحوصات دم ليتفقّد عدد كريات الدم خلال تلقيك علاج فينكليكستا.</li><li dir="RTL">حالات العدوى: حدث الموت وحالات العدوى الخطيرة مثل ذات الرئة وعدوى الدم (الإنتان) في أثناء العلاج بـ فينكليكستا. سيضعك مقدّم الرعاية الصحية تحت مراقبة وثيقة وسيعالجك على الفور إذا أصبت بالحمى أو إذا ظهرت أي من علامات العدوى في أثناء العلاج بـ فينكليكستا. &nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ مقدّم الرعاية الصحيّة &nbsp;مباشرةً إذا ارتفعت حرارتك أو ظهرت عليك أي من أعراض الالتهاب في أثناء العلاج بواسطة &nbsp;فينكليكستا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الأكثر شيوعا التي ترافق تناول فينكليكستا عند استعماله بالاشتراك مع أوبينوتوزوماب أو ريتوكسيماب أو لوحده عند المصابين بسرطان الدم الليمفاوي المزمن أو ليمفوما الخلايا الليمفاوية الصغيرة تشمل: مع سرطان الدم الليمفاوي المزمن تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كريات الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى القسم العلوي من الجهاز التنفسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام عضلية ومفصلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الذراعين، الساقين، اليدين والقدمين</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الأكثر شيوعا التي ترافق تناول فينكليكستا عند استعماله لوحده&nbsp; لدى المصابين بسرطان الدم الليمفاوي المزمن/ ليمفوما الخلايا الليمفاوية الصغيرة تشمل ما يلي:</p><ul><li dir="RTL">الإسهال</li><li dir="RTL">الغثيان</li><li dir="RTL">عدوى القسم العلوي من الجهاز التنفسي</li><li dir="RTL">انخفاض عدد كريات الدم الحمراء</li><li dir="RTL">التعب</li><li dir="RTL">انخفاض عدد الصفائح الدموية</li><li dir="RTL">آلام عضلية ومفصلية</li><li dir="RTL">تورم الذراعين، الساقين، اليدين والقدمين</li><li dir="RTL">السعال</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الأكثر شيوعا التي ترافق تناول فينكليكستا بالاشتراك مع آزاكتيدين أو ديسيتابين أو جرعة منخفضة من سيتارابين لعلاج المصابين بسرطان الدم النقوي الحادّ تشمل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة مع انخفاض عدد الكريات البيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كريات الدم الحمراء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الذراعين، الساقين، اليدين والقدمين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيّؤ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة (البطن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات أو الظهر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الحلق</p><p dir="RTL">قد يسبب فينكليكستا بمشاكل خصوبة لدى الرجال ما قد يؤثر على قدرتك لتكون أبًا. تحدث إلى مقدّم الرعاية الصحيّة إذا كان لديك هواجس من حيث الخصوبة.</p><p dir="RTL">ما ذكر أعلاه ليس كافة التأثيرات الجانبية المحتملة لـ فينكليكستا. للاطلاع على مزيد من المعلومات، اسأل مقدم الرعاية الصحية أو الصيدلاني.</p><p dir="RTL">اتصل بطبيبك للحصول على نصيحة طبية بشأن التأثيرات الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ابقه بعيدًا عن مرأى الأطفال ومتناول أيديهم .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خزّن فينكليكستا على درجة 30 مئوية (86 فهرنهايت) أو أقل.</p><p dir="RTL">بالنسبة للأفراد المصابين بسرطان الدم الليمفاوي المزمن/ ليمفوما الخلايا الليمفاوية الصغيرة، يجب حفظ أقراص فينكليكستا في عبوتها الأصلية في أثناء الأسابيع الأربعة الأولى من العلاج. لا تنقل الأقراص إلى علبة مختلفة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكوّن نشط: </strong>فنيتوكلاكس</p><p dir="RTL"><strong>مكونات غير نشطة:</strong> كوبوفيدون وثاني أوكسيد السيليكون الغروي وبوليسوربات 80 وفومارات ستيريل الصوديوم وفوسفات ثنائي الكالسيوم.</p><p dir="RTL">وتشمل أقراص الـ10 والـ100 مغ ما يلي: أكسيد الحديد الأصفر وكحول متعدد الفاينيل والجيليكول المتعدد الاثيلين ومسحوق التالك وثُنائيُّ اكسيد التيتانيوم. وتشمل أقراص الـ50 مغ المغلفة أيضًا: أكسيد الحديد الأصفر والأحمر والأسود وكحول متعدد الفاينيل ومسحوق التالك والجيليكول المتعدد الاثيلين وثُنائيُّ اكسيد التيتانيوم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيف يبدو دواء </strong><strong>فينكليكستا ومحتويات العلبة</strong></p><p dir="RTL">أقراص فينكليكستا الـ10 مغ المغلفة دائرية وثنائية التحدب ولونها أصفر باهت، محفور عليها حرف V من جهة والرقم 10 من جهة أخرى.</p><p dir="RTL">أقراص فينكليكستا الـ50 مغ المغلفة مستطيلة وثنائية التحدب لونها بيج محفور عليها حرف V من جهة والرقم 50 من جهة أخرى.</p><p dir="RTL">أقراص فينكليكستا الـ100 مغ المغلفة مستطيلة وثنائية التحدب لونها أصفر باهت محفور عليها حرف V من جهة والرقم 100 من جهة أخرى.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right"><tbody><tr><td style="vertical-align:top"><p dir="RTL">عرض التعبئة والتغليف</p></td><td style="vertical-align:top"><p dir="RTL"><strong>عدد الأقراص</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">علبة البداية</p></td><td style="vertical-align:top"><p dir="RTL">تتضمن كل علبة 4 علب محفظات من فقاعات أسبوعية:</p><ul><li dir="RTL">الأسبوع 1: (14 قرصًا X 10 مغ)</li><li dir="RTL">الأسبوع 2: ( 7 أقراص X 50 مغ)</li><li dir="RTL">الأسبوع 3: (7 أقراص X 100 مغ)</li><li dir="RTL">الأسبوع 4: (14 قرصًا X 100 مغ)</li></ul></td></tr><tr><td style="vertical-align:top"><p dir="RTL">محفظة الـ10 مغ</p></td><td style="vertical-align:top"><p dir="RTL">14 قرصًا X 10 مغ</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">محفظة الـ50 مغ</p></td><td style="vertical-align:top"><p dir="RTL">7 أقراص X 50 مغ</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">وحدة جرعة الـ10مغ</p></td><td style="vertical-align:top"><p dir="RTL">قرصان X 10 مغ</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">وحدة جرعة الـ50 مغ</p></td><td style="vertical-align:top"><p dir="RTL">قرص X 50 مغ</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">وحدة جرعة الـ100 مغ</p></td><td style="vertical-align:top"><p dir="RTL">قرص X 100 مغ</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قنينة الـ100 مغ</p></td><td style="vertical-align:top"><p dir="RTL">120 قرصًا X 100 مغ</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة أبفي</p><p dir="RTL">شمال شيكاغو</p><p dir="RTL">إلينوي 60064</p><p dir="RTL">شيكاغو</p><p dir="RTL">الولايات المتحدة</p><p dir="RTL"><strong>صنع من قبل:</strong></p><p dir="RTL">شركة أبفي إيرلندا أن أل بي.في.</p><p dir="RTL">طريق مانورهاميلتون</p><p dir="RTL">سليغو، إيرلندا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعبئة وتغليف:</strong></p><p dir="RTL">شركة أبفي أنك 1 شارع &nbsp;ووكيغان، شمال شيكاغو، إلينوي 60664 الولايات المتحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على معلومات حول هذا المنتج الدوائي، يرجى الاتصال بالوكيل المحلي لمالك حق التسويق:</p><p dir="RTL"><strong><u>شركة أبفي لإنتاج الأدوية البيولوجية المحدودة المسؤولية (</u></strong><strong><u>Abbvie Biopharmaceuticals GmbH </u></strong><strong><u>)</u></strong></p><p dir="RTL">الخط الساخن: 2010 828 55 00966</p><p dir="RTL">صندوق البريد: Pv.Saudiarabia@abbvie.com</p><p>&nbsp;</p><p dir="RTL">د&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمت الموافقة الأخيرة على هذه النشرة في يوليو 2019</p><p dir="RTL">&nbsp;</p><p dir="RTL">ه&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للإبلاغ عن أي أعراض جانبية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>المملكة العربية السعودية:</u></strong></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية - الهيئة العامة للغذاء والدواء</p><p dir="RTL">فاكس: +966-11-205-7662</p><p dir="RTL">للاتصال بالمركز: +966-11-2038222</p><p dir="RTL">الخطوط الفرعية: 2317 - 2356 - 2353 - 2354 - 2334</p><p dir="RTL">لمكالمة مجانية الاتصال على: 8002490000</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى الاتصال بالجهة المختصة والمعنية</p><p><br /><img alt="" width="615" height="355" src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت الموافقة الأخيرة على هذه النشرة في يوليو 2019


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VENCLEXTA 10 mg film-coated tablets
VENCLEXTA 50 mg film-coated tablets
 VENCLEXTA 100 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
VENCLEXTA 10 mg film-coated tablets
Each film-coated tablet contains 10 mg of venetoclax.

VENCLEXTA 50 mg film-coated tablets
Each film-coated tablet contains 50 mg of venetoclax.

VENCLEXTA 100 mg film-coated tablets
Each film-coated tablet contains 100 mg of venetoclax.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Table 1. VENCLEXTA Tablet Strength and Description
Tablet Strength	Description of Tablet
10 mg	Round, biconvex shaped, pale yellow film-coated
tablet debossed with “V” on one side and “10” on the other side
50 mg	Oblong, biconvex shaped, beige film-coated tablet
debossed with “V” on one side and “50” on the other side
100 mg	Oblong, biconvex shaped, pale yellow film-coated
tablet debossed with “V” on one side and “100”
on the other side



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</u></strong></p><p><strong>&nbsp;</strong></p><p>VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).</p><p>&nbsp;</p><p>See Section 4.2 DOSE AND METHOD OF ADMINISTRATION for details of monotherapy and combination use and Section 5.3 Pre-clinical safety data: CLININCAL STUDIES</p><p>&nbsp;</p><p><strong><u>Acute Myeloid Leukemia</u></strong></p><p><strong>&nbsp;</strong></p><p>VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose</p><p>cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who</p><p>are age 75 years or older, or who have comorbidities that preclude use of intensive induction</p><p>chemotherapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>This indication is approved under accelerated approval based on response rates <em>[see Clinical</em></p><p><em>Studies]</em>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Recommended Dosage</strong></p><p>&nbsp;</p><p>Assess patient-specific factors for level of risk of tumor lysis syndrome (TLS) and provide prophylactic hydration and anti-hyperuricemics to patients prior to first dose of VENCLEXTA to reduce risk of TLS.</p><p>&nbsp;</p><p>Instruct patients to take VENCLEXTA tablets with a meal and water at approximately the same time each day. VENCLEXTA tablets should be swallowed whole and not chewed, crushed, or broken prior to swallowing.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</u></p><p>All VENCLEXTA dose regimens begin with a 5-week ramp-up.</p><p><em>VENCLEXTA 5-week Dose Ramp-Up Schedule</em></p><p>&nbsp;</p><p>Administer the VENCLEXTA dose according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg as shown in Table 2. The 5-week ramp-up dosing schedule is designed to gradually reduce tumor burden (debulk) and decrease the risk of TLS.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 2. Dosing Schedule for Ramp-Up Phase</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><s>Week</s></strong></p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>VENCLEXTA Daily Dose</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr></tbody></table></td></tr><tr><td style="text-align:center">week 1</td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:center">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;20 mg</p></td></tr><tr><td style="text-align:center; vertical-align:top">&nbsp;</td></tr></tbody></table></td></tr><tr><td style="text-align:center">week 2</td><td style="text-align:center">&nbsp;50 mg</td></tr><tr><td style="text-align:center">week 3</td><td style="text-align:center">100 mg</td></tr><tr><td style="text-align:center">week 4</td><td style="text-align:center">200 mg</td></tr><tr><td style="text-align:center">week 5 and beyonde</td><td style="text-align:center">400 mg</td></tr></tbody></table><p>&nbsp;<p><br />The CLL/SLL Starting Pack provides the first 4 weeks of VENCLEXTA according to the ramp-up schedule. The 400 mg dose is achieved using 100 mg tablets supplied in bottles.</p></p><p>&nbsp;</p><p><u>VENCLEXTA in Combination with Obinutuzumab</u></p><p>Start obinutuzumab administration at 100 mg on Cycle 1 Day 1, followed by 900 mg on Cycle 1 Day 2. Administer 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle, for a total of 6 cycles. Refer to the obinutuzumab prescribing information for recommended obinutuzumab dosing information.</p><p>&nbsp;</p><p>On Cycle 1 Day 22, start VENCLEXTA according to the 5-week ramp-up schedule (see Table 1). After completing the ramp-up schedule on Cycle 2 Day 28, patients should continue VENCLEXTA 400 mg once daily from Cycle 3 Day 1 until the last day of Cycle 12.</p><p>&nbsp;</p><p><u>VENCLEXTA in Combination with Rituximab</u></p><p>Start rituximab administration after the patient has completed the 5-week dose ramp-up schedule with VENCLEXTA (see Table 1) and has received the 400 mg dose of VENCLEXTA for 7 days. Administer rituximab on Day 1 of each 28-day cycle for 6 cycles, with rituximab dosed at 375 mg/m<sup>2</sup> intravenously for Cycle 1 and 500 mg/m<sup>2</sup> intravenously for Cycles 2-6.</p><p>&nbsp;</p><p>Patients should continue VENCLEXTA 400 mg once daily for 24 months from Cycle 1 Day 1 of rituximab.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>VENCLEXTA as Monotherapy</u></p><p>The recommended dose of VENCLEXTA is 400 mg once daily after the patient has completed the 5-week dose ramp-up schedule. VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed.</p><p><u>Acute Myeloid Leukemia</u></p><p>The dose of VENCLEXTA depends upon the combination agent.</p><p>The VENCLEXTA dosing schedule (including ramp-up) is shown in Table 3. Initiate the azacitidine or decitabine or low-dose cytarabine on Day 1.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Table 3. Dosing Schedule for Ramp-up Phase in Patients with AML</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>VENCLEXTA</strong></p><p><strong>Daily Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 1</p></td><td colspan="2" style="vertical-align:top"><p>100 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 2</p></td><td colspan="2" style="vertical-align:top"><p>200 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 3</p></td><td colspan="2" style="vertical-align:top"><p>400 mg</p></td></tr><tr><td style="vertical-align:top"><p>Days 4 and beyond</p></td><td style="vertical-align:top"><p>400 mg</p><p>when dosing in combination with</p><p><strong>azacitidine or decitabine</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>600 mg</p><p>when dosing in combination with</p><p><strong>low-dose cytarabine</strong></p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Continue VENCLEXTA, in combination with azacitidine or decitabine or low-dose cytarabine,</p><p>until disease progression or unacceptable toxicity is observed.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Risk Assessment and Prophylaxis for Tumor Lysis Syndrome</strong></p><p>Patients treated with VENCLEXTA may develop tumor lysis syndrome. Refer to the appropriate<strong> </strong>section below for specific details on management. Assess patient-specific factors for level of risk<strong> </strong>of tumor lysis syndrome (TLS) and provide prophylactic hydration and anti-hyperuricemics to<strong> </strong>patients prior to first dose of VENCLEXTA to reduce risk of TLS.</p><p><strong>&nbsp;</strong></p><p><u>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</u></p><p><strong><u>&nbsp;</u></strong></p><p>VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS in the initial 5-week ramp-up phase. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase.</p><p>&nbsp;</p><p>The risk of TLS is a continuum based on multiple factors, including tumor burden and comorbidities. Reduced renal function (creatinine clearance [CLcr] &lt;80 mL/min) further increases the risk. Perform tumor burden assessments, including radiographic evaluation (e.g., CT scan), assess blood chemistry (potassium, uric acid, phosphorus, calcium, and creatinine) in all patients and correct pre- existing abnormalities prior to initiation of treatment with VENCLEXTA. The risk may decrease as tumor burden decreases.</p><p>Table 4 below describes the recommended TLS prophylaxis and monitoring during VENCLEXTA</p><p>treatment based on tumor burden determination from clinical trial data. Consider all patient comorbidities before final determination of prophylaxis and monitoring schedule.</p><p>&nbsp;</p><p>Table 4. Recommended TLS Prophylaxis Based on Tumor Burden in patients with CLL/SLL &nbsp;</p><p dir="LTR">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Tumor Burden</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Prophylaxis</strong></p></td><td style="vertical-align:top"><p dir="LTR"><strong>Blood Chemistry</strong></p><p dir="LTR"><strong>Monitoring</strong><strong>c,d</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="LTR"><strong>Hydration</strong><strong>a&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p dir="LTR"><strong>Anti- hyperuricemics</strong></p></td><td style="vertical-align:top"><p dir="LTR"><strong>Setting and Frequency of Assessments</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">LOW</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">All LN &lt;5 cm AND<br />ALC &lt;25 x10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p dir="LTR">Oral<br />(1.5-2 L)</p></td><td style="vertical-align:top"><p dir="LTR">Allopurinol<sup>b</sup></p></td><td style="vertical-align:top"><p dir="LTR">Outpatient</p><p dir="LTR">&bull;&nbsp;&nbsp;&nbsp;&nbsp; For first dose of 20 mg and 50 mg: Pre-dose, 6 to 8 hours, 24 hours</p><p dir="LTR">For subsequent ramp-up doses: Pre-dose</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Medium</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Any LN 5 cm to</p><p dir="LTR">&lt;10 cm</p><p dir="LTR">OR</p><p dir="LTR">ALC &ge;25 x109/L</p></td><td style="vertical-align:top"><p dir="LTR">Oral</p><p dir="LTR">(1.5-2 L) and consider additional intravenous</p></td><td style="vertical-align:top"><p dir="LTR">Allopurinol</p></td><td style="vertical-align:top"><p dir="LTR">Outpatient</p><p dir="LTR">&bull;&nbsp;&nbsp;&nbsp;&nbsp; For first dose of 20 mg and 50 mg: Pre-dose, 6 to 8 hours, 24 hours</p><p dir="LTR">&bull;&nbsp;&nbsp;&nbsp;&nbsp; For subsequent ramp-up doses: Pre-dose</p><p dir="LTR">For first dose of 20 mg and 50 mg: Consider hospitalization for patients with CrCl &lt;80ml/min; see below for monitoring in hospital</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">High</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Any LN &ge;10 cm</p><p dir="LTR">OR</p><p dir="LTR">ALC &ge;25 x109/L AND</p><p dir="LTR">any LN &ge;5 cm</p></td><td style="vertical-align:top"><p dir="LTR">Oral (1.5-2L) and intravenous (150-200 mL/hr as tolerated)</p></td><td style="vertical-align:top"><p dir="LTR">Allopurinol; consider rasburicase if baseline uric acid is elevated</p></td><td style="vertical-align:top"><p dir="LTR">In hospital</p><p dir="LTR">&bull;&nbsp;&nbsp;&nbsp;&nbsp; For first dose of 20 mg and 50 mg: Pre-dose, 4, 8, 12 and 24 hours</p><p dir="LTR">Outpatient</p><p dir="LTR">For subsequent ramp-up doses: Pre-dose, 6 to 8 hours, 24 hours</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p dir="LTR">ALC = absolute lymphocyte count; LN = lymph node.</p><p dir="LTR">aAdminister intravenous hydration for any patient who cannot tolerate oral hydration.</p><p dir="LTR">bStart allopurinol or xanthine oxidase inhibitor 2 to 3 days prior to initiation of VENCLEXTA. cEvaluate blood chemistries (potassium, uric acid, phosphorus, calcium, and creatinine); review in real time.</p><p dir="LTR">dFor patients at risk of TLS, monitor blood chemistries at 6 to 8 hours and at 24 hours at each subsequent ramp-up dose.</p></td></tr></tbody></table><p dir="LTR"><u style="text-align:unset">Acute Myeloid Leukemia</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All patients should have white blood cell count less than 25 &times; 109/L prior to initiation of VENCLEXTA. Cytoreduction prior to treatment may be required.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to first VENCLEXTA dose, provide all patients with prophylactic measures including adequate hydration and anti-hyperuricemic agents and continue during ramp-up phase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assess blood chemistry (potassium, uric acid, phosphorus, calcium, and creatinine) and correct pre-existing abnormalities prior to initiation of treatment with VENCLEXTA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor blood chemistries for TLS at pre-dose, 6 to 8 hours after each new dose during ramp-up and 24 hours after reaching final dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with risk factors for TLS (e.g., circulating blasts, high burden of leukemia involvement in bone marrow, elevated pretreatment lactate dehydrogenase (LDH) levels, or reduced renal function) additional measures should be considered, including increased laboratory monitoring and reducing VENCLEXTA starting dose.</p><p>&nbsp;</p><p>Dose Modifications Based on Toxicities</p><p><u>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</u></p><p>Interrupt dosing or reduce dose for toxicities. See Table 5 and Table 6 for recommended dose</p><p>modifications for toxicities related to VENCLEXTA. For patients who have had a dosing interruption greater than 1 week during the first 5 weeks of ramp-up phase or greater than 2 weeks after completing the ramp-up phase, reassess for risk of TLS to determine if reinitiation with a reduced dose is necessary (e.g., all or some levels of the dose ramp-up schedule).</p><p>Table 5. Recommended VENCLEXTA Dose Modifications for Toxicities<sup>a </sup>in CLL/SLL</p><p>&nbsp;</p><p dir="LTR">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="LTR"><strong>Event</strong></p></td><td style="vertical-align:top"><p dir="LTR"><strong>Occurrence</strong></p></td><td style="vertical-align:top"><p dir="LTR"><strong>Action</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="LTR" style="text-align:center">Tumor Lysis Syndrome</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p dir="LTR" style="text-align:center">Blood chemistry changes or symptoms suggestive of TLS</p></td><td rowspan="3" style="vertical-align:top"><p dir="LTR">Any</p></td><td style="vertical-align:top"><p dir="LTR">Withhold the next day&rsquo;s dose. If resolved within</p><p dir="LTR">24 to 48 hours of last dose, resume at the same dose.</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">For any blood chemistry changes requiring more than 48 hours to resolve, resume at a reduced dose (see Table 6) <em>[</em>Posology and method of administration<em>] </em></p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">For any events of clinical TLS,b resume at a reduced dose following resolution (see Table 6).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="LTR" style="text-align:center">Non-Hematologic Toxicities</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="LTR">Grade 3 or 4 non- hematologic toxicities</p></td><td style="vertical-align:top"><p dir="LTR">1st occurrence</p></td><td style="vertical-align:top"><p dir="LTR">Interrupt VENCLEXTA.</p><p dir="LTR">Once the toxicity has resolved to Grade 1 or baseline level, VENCLEXTA therapy may be</p><p dir="LTR">resumed at the same dose. No dose modification is required.</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">2nd and subsequent occurrences</p></td><td style="vertical-align:top"><p dir="LTR">Interrupt VENCLEXTA.</p><p dir="LTR">Follow dose reduction guidelines in Table 6 when resuming treatment with VENCLEXTA after</p><p dir="LTR">resolution. A larger dose reduction may occur at the discretion of the physician.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="LTR">Hematologic Toxicities</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="LTR">Grade 3 neutropenia with infection or fever;</p><p dir="LTR">or Grade 4 hematologic</p><p dir="LTR">toxicities (except lymphopenia).</p></td><td style="vertical-align:top"><p dir="LTR">1st occurrence</p></td><td style="vertical-align:top"><p dir="LTR">Interrupt VENCLEXTA.</p><p dir="LTR">To reduce the infection risks associated with neutropenia, granulocyte-colony stimulating factor</p><p dir="LTR">(G-CSF) may be administered with</p><p dir="LTR">VENCLEXTA if clinically indicated. Once the toxicity has resolved to Grade 1 or baseline level,</p><p dir="LTR">VENCLEXTA therapy may be resumed at the</p><p dir="LTR">same dose.</p><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">2nd and subsequent occurrences</p></td><td style="vertical-align:top"><p dir="LTR">Interrupt VENCLEXTA.</p><p dir="LTR">Consider using G-CSF as clinically indicated. Follow dose reduction guidelines in Table 6 &nbsp;when</p><p dir="LTR">resuming treatment with VENCLEXTA after resolution. A larger dose reduction may occur at the discretion of the physician.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="LTR">Consider discontinuing VENCLEXTA for patients who require dose reductions to less than 100 mg for more than 2 weeks.</p><p dir="LTR">aAdverse reactions were graded using NCI CTCAE version 4.0.</p><p dir="LTR">bClinical TLS was defined as laboratory TLS with clinical consequences such as acute renal failure, cardiac arrhythmias, or sudden death and/or seizures.</p></td></tr></tbody></table><p dir="LTR">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 6. Dose Modification for Toxicity During VENCLEXTA Treatment in CLL/SLL</p><table border="1" cellspacing="0" cellpadding="0" style="width:709px"><tbody><tr><td style="vertical-align:top"><p><strong>Dose at Interruption, mg</strong></p></td><td style="vertical-align:top"><p><strong>Restart Dose, mg</strong><strong>a</strong></p></td></tr><tr><td style="vertical-align:top"><p>400</p></td><td style="vertical-align:top"><p>300</p></td></tr><tr><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>200</p></td></tr><tr><td style="vertical-align:top"><p>200</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>aDuring the ramp-up phase, continue the reduced dose for 1 week before increasing the dose.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Acute Myeloid Leukemia</u></p><p>Monitor blood counts frequently through resolution of cytopenias. Management of some adverse reactions may require dose interruptions or permanent discontinuation of VENCLEXTA. Table 7 shows the dose modification guidelines for hematologic toxicities.</p><p><strong>Table 7. Recommended Dose Modifications for Toxicities</strong><strong>a </strong><strong>in AML</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Event</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Occurrence</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hematologic Toxicities</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Grade 4 neutropenia</p><p>with or without fever or</p><p>infection; or Grade 4</p><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>Occurrence prior to achieving remission</p></td><td style="vertical-align:top"><p>Transfuse blood products, administer</p><p>prophylactic and treatment anti-infectives as clinically indicated.</p><p>In most instances, VENCLEXTA and</p><p>azacitidine, decitabine, or low-dose cytarabine cycles should not be interrupted due to cytopenias prior to achieving remission.</p></td></tr><tr><td style="vertical-align:top"><p>First occurrence after</p><p>achieving remission</p><p>and lasting at least 7</p><p>days</p></td><td style="vertical-align:top"><p>Delay subsequent treatment cycle of</p><p>VENCLEXTA and azacitidine, decitabine, or low-dose cytarabine and monitor blood counts.</p><p>Administer granulocyte-colony stimulating</p><p>factor (G-CSF) if clinically indicated for neutropenia. Once the toxicity has resolved to</p><p>Grade 1 or 2, resume VENCLEXTA therapy at the same dose in combination with azacitidine or decitabine or low-dose cytarabine.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Subsequent occurrences</p><p>in cycles after achieving</p><p>remission and lasting 7</p><p>days or longer</p></td><td style="vertical-align:top"><p>Delay subsequent treatment cycle of</p><p>VENCLEXTA and azacitidine, or decitabine, or low-dose cytarabine and monitor blood counts.</p><p>Administer G-CSF if clinically indicated for neutropenia. Once the toxicity has resolved to</p><p>Grade 1 or 2, resume VENCLEXTA therapy at the same dose and the duration reduced by 7 days for each subsequent cycle.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>Adverse reactions were graded using NCI CTCAE version 4.0.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Dosage Modifications for Concomitant Use with Strong or Moderate CYP3A Inhibitors or P-gp Inhibitors</p><p>&nbsp;</p><p>Table 8 describes VENCLEXTA contraindication or dosage modification based on concomitant use with a strong or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderate CYP3A inhibitor or P-gp inhibitor <em>[see Drug Interactions] </em>at initiation, during, or after the ramp-up phase.</p><p>&nbsp;</p><p>Resume the VENCLEXTA dosage that was used prior to concomitant use of a strong or moderate CYP3A inhibitor or P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor [see Posology and method of administration <em>&nbsp;and Drug Interactions]</em>.</p><p><s>&nbsp;</s></p><p>Table 8. Management of Potential VENCLEXTA Interactions with CYP3A and P-gp Inhibitors</p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Coadministered drug</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Initiation and Ramp- Up</strong></p><p><strong>Phase</strong></p></td><td style="vertical-align:top"><p><strong>Steady Daily Dose</strong></p><p><strong>(After Ramp-Up Phase)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Posaconazole</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>CLL/SLL</p></td><td colspan="2" style="vertical-align:top"><p>Contraindicated</p></td><td rowspan="2" style="vertical-align:top"><p>Reduce the VENCLEXTA dose to 70 mg</p></td></tr><tr><td style="vertical-align:top"><p>AML</p></td><td colspan="2" style="vertical-align:top"><p>Day 1 &ndash; 10 mg</p><p>Day 2 &ndash; 20 mg</p><p>Day 3 &ndash; 50 mg</p><p>Day 4 &ndash; 70 mg</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Other strong CYP3A</p><p>inhibitor</p></td><td colspan="2" style="vertical-align:top"><p>CLL/SLL</p></td><td style="vertical-align:top"><p>Contraindicated</p></td><td rowspan="2" style="vertical-align:top"><p>Reduce VENCLEXTA dose to 100 mg.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>AML</p></td><td style="vertical-align:top"><p>Day 1 &ndash; 10 mg</p><p>Day 2 &ndash; 20 mg</p><p>Day 3 &ndash; 50 mg</p><p>Day 4 &ndash; 100 mg</p></td></tr><tr><td style="vertical-align:top"><p>Moderate CYP3A</p><p>inhibitor</p></td><td colspan="4" rowspan="2" style="vertical-align:top"><p>Reduce the VENCLEXTA dose by at least 50%.</p></td></tr><tr><td style="vertical-align:top"><p>P-gp inhibitor</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>In patients with CLL/SLL, consider alternative medications or reduce the VENCLEXTA dose as described in Table 8.</p></td></tr></tbody></table><p><br /><em style="text-align:unset"><u>Dosage Modifications for Patients with Severe Hepatic Impairment</u></em></p><p>Reduce the VENCLEXTA once daily dose by 50% for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more closely for signs of toxicity <em>[see Use in Specific Populations and Clinical Pharmacology].</em></p><p><u>&nbsp;</u></p><p><em><u>Missed Dose</u></em></p><p>If the patient misses a dose of VENCLEXTA within 8 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal daily dosing schedule. If a patient misses a dose by more than 8 hours, the patient should not take the missed dose and should resume the usual dosing schedule the next day.</p><p>&nbsp;</p><p>If the patient vomits following dosing, no additional dose should be taken that day. The next prescribed dose should be taken at the usual time.</p><p>&nbsp;</p><p><strong><u>Use &nbsp;in &nbsp;Specific &nbsp;Populations</u></strong></p><p>&nbsp;</p><p><strong><u>Pediatric &nbsp;Use</u></strong></p><p>Safety and effectiveness have not been established in pediatric patients</p><p>&nbsp;</p><p>In a juvenile toxicology study, mice were administered venetoclax at 10, 30, or 100 mg/kg/day by oral gavage from 7 to 60 days of age. Clinical signs of toxicity included decreased activity, dehydration, skin pallor, and hunched posture at &ge;30 mg/kg/day. In addition, mortality and body weight effects occurred at 100 mg/kg/day. Other venetoclax-related effects were reversible decreases in lymphocytes at &ge;10 mg/kg/day; a dose of 10 mg/kg/day is approximately 0.06 times the clinical dose of 400 mg on a mg/m2 basis for a 20 kg child.</p><p><u>&nbsp;</u></p><p><strong><u>Geriatric &nbsp;Use</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><u>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</u></p><p><strong><u>&nbsp;</u></strong></p><p>Of the 352 patients with previously treated CLL/SLL evaluated for safety from 3 open-label trials of VENCLEXTA monotherapy, 57% (201/352) were &ge;65 years of age and 18% (62/352) were &ge;75 years of age.</p><p>No clinically meaningful differences in safety and effectiveness were observed between older and younger patients in the combination and monotherapy studies.</p><p>&nbsp;</p><p><strong><u>Acute Myeloid Leukemia</u></strong></p><p>Of the 67 patients treated with VENCLEXTA in combination with azacitidine in the clinical trial, 96% were &ge;65 years of age and 50% were &ge; 75 years of age. Of the 13 patients treated with VENCLEXTA in combination with decitabine in the clinical trial, 100% were &ge;65 years of age and 26% were &ge; 75 years of age. Of the 61 patients treated with VENCLEXTA in combination with low-dose cytarabine, 97% were &ge;65 years of age and 66% were &ge;75 years of age.</p><p>&nbsp;</p><p>The efficacy and safety data presented in the Adverse Reactions and Clinical Studies sections were obtained from these patients [see Adverse Reactions (6.2) and Clinical Studies (14.2)].</p><p>There are insufficient patient numbers to show differences in safety and effectiveness between geriatric and younger patients.</p><p>&nbsp;</p><p><u>Renal &nbsp;Impairment</u></p><p>&nbsp;</p><p>Due to the increased risk of TLS, patients with reduced renal function (CLcr &lt;80 mL/min, calculated by Cockcroft-Gault formula require more intensive prophylaxis and monitoring to reduce the risk of TLS when initiating treatment with VENCLEXTA.</p><p>&nbsp;</p><p>No dose adjustment is recommended for patients with mild or moderate renal impairment (CLcr &ge; 30 mL/min [see Clinical Pharmacology (12.3)]. A recommended dose has not been determined for patients with severe renal impairment (CLcr &lt; 30 mL/min) or patients on dialysis.</p><p>&nbsp;</p><p><u>Hepatic &nbsp;Impairment</u></p><p>&nbsp;</p><p>No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.</p><p>Reduce the dose of VENCLEXTA for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more closely for signs of toxicity [<em>see</em> Posology and method of administration and Clinical Pharmacology].</p><p><u>&nbsp;</u></p><p><u>Method &nbsp;of &nbsp;administration</u></p><p>&nbsp;</p><p>VENCLEXTA should be taken orally once daily until disease progression or unacceptable toxicity is observed. Instruct patients to take VENCLEXTA tablets with a meal and water at approximately the same time each day. VENCLEXTA tablets should be swallowed whole and not chewed, crushed, or broken prior to swallowing.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during ramp-up phase is contraindicated in patients with CLL/SLL due to the potential for increased risk of tumor lysis syndrome.
Concomitant use of preparations containing St. John’s wort (see sections 4.4 and 4.5). 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tumor &nbsp;&nbsp;Lysis &nbsp;&nbsp;Syndrome</u></p><p>&nbsp;</p><p>Tumor lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients with previously treated CLL with high tumor burden when treated with VENCLEXTA.</p><p>&nbsp;</p><p>In patients with CLL, the current (5 week) dose ramp-up, TLS prophylaxis and monitoring, the rate of TLS was 2% in the VENCLEXTA CLL monotherapy studies. The rate of TLS remained consistent with VENCLEXTA in combination with rituximab. With a 2 to 3 week dose ramp-up and higher starting dose in patients with CLL/SLL, the TLS rate was 13% and included deaths and renal failure.</p><p>&nbsp;</p><p>VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS at initiation and during the ramp-up phase. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase.</p><p>&nbsp;</p><p>The risk of TLS is a continuum based on multiple factors, including tumor burden and comorbidities. Reduced renal function further increases the risk. Patients should be assessed for risk and should receive appropriate prophylaxis for TLS, including hydration and anti- hyperuricemics. Monitor blood chemistries and manage abnormalities promptly. Interrupt dosing if needed. Employ more intensive measures (intravenous hydration, frequent monitoring, hospitalization) as overall risk increases.</p><p>&nbsp;</p><p>Concomitant use of VENCLEXTA with P-gp inhibitors strong or moderate CYP3A inhibitors increases venetoclax exposure, may increase the risk of TLS at initiation and during ramp-up phase and <s>may</s> requires VENCLEXTA dose adjustment.</p><p>&nbsp;</p><p><u>Neutropenia</u></p><p><s>&nbsp;</s></p><p>In patients with CLL, Grade 3 or 4 neutropenia developed in 63% to 64% of patients and Grade 4 neutropenia developed in 31% to 33% of patients treated with VENCLEXTA in combination and monotherapy studies (see Tables 10, 12, 14). Febrile neutropenia occurred in 4% to 6% of patients treated with VENCLEXTA in combination and monotherapy studies</p><p>&nbsp;</p><p>In patients with AML, baseline neutrophil counts worsened in 97% to 100% of patients treated with VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine. Neutropenia can recur with subsequent cycles of therapy.</p><p>&nbsp;</p><p>Monitor complete blood counts throughout the treatment period. Interrupt dosing or reduce dose for severe neutropenia. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF).</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>Fatal and serious infections such as pneumonia and sepsis have occurred in patients treated with VENCLEXTA. Monitor patients closely for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and higher infection.</p><p><u>&nbsp;</u></p><p><u>Immunization</u></p><p>&nbsp;</p><p>Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until</p><p>B-cell recovery occurs. The safety and efficacy of immunization with live attenuated vaccines during or following VENCLEXTA therapy have not been studied. Advise patients that vaccinations may be less effective.</p><p>&nbsp;</p><p><u>Embryo-Fetal Toxicity</u></p><p>&nbsp;</p><p>Based on its mechanism of action and findings in animals, VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. In an embryo-fetal study conducted in mice, administration of venetoclax to pregnant animals at exposures equivalent to that observed in patients at the recommended dose of 400 mg daily resulted in post-implantation loss and decreased fetal weight. There are no adequate and well-controlled studies in pregnant woman using VENCLEXTA. Advise females of reproductive potential to avoid pregnancy during treatment. If VENCLEXTA is used during pregnancy or if the patient becomes pregnant while taking VENCLEXTA, the patient should be apprised of the potential hazard to the fetus.</p><p>&nbsp;</p><p><u>Increased Mortality in Patients with Multiple Myeloma when VENCLEXTA is Added to Bortezomib and Dexamethasone</u></p><p>&nbsp;</p><p>In a randomized trial (BELLINI; NCT02755597) in patients with relapsed or refractory multiple myeloma, the addition of VENCLEXTA to bortezomib plus dexamethasone, a use for which VENCLEXTA is not indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with VENCLEXTA in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of other drugs on Venclexta</u></p><p>&nbsp;</p><p><u>Strong or moderate &nbsp;CYP3A &nbsp;Inhibitors or P-gp inhibitors</u></p><p><u>&nbsp;</u></p><p>Concomitant use with a strong or moderate CYP3A inhibitor or a P-gp inhibitor increases venetoclax Cmax and AUCinf, which may increase VENCLEXTA toxicities, including the risk of TLS <em>[see Warnings and Precautions (5)]</em>.</p><p>Concomitant use with a strong CYP3A inhibitor at initiation and during the ramp-up phase in patients with CLL/SLL is contraindicated.</p><p>&nbsp;</p><p>In patients with CLL/SLL taking a steady daily dosage (after ramp-up phase), consider alternative medications or adjust VENCLEXTA dosage and closely monitor for signs of VENCLEXTA toxicities.</p><p>&nbsp;</p><p>In patients with AML, adjust VENCLEXTA dosage and closely monitor for signs of VENCLEXTA toxicities.</p><p>&nbsp;</p><p>Resume the VENCLEXTA dosage that was used prior to concomitant use with a strong or moderate CYP3A inhibitor or a P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor.</p><p>&nbsp;</p><p>Avoid grapefruit products, Seville oranges, and starfruit during treatment with VENCLEXTA, as they contain inhibitors of CYP3A.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Strong or Moderate CYP3A Inducers</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>Concomitant use with a strong CYP3A inducer decreases venetoclax Cmax and AUCinf, which may decrease VENCLEXTA efficacy. Avoid concomitant use of VENCLEXTA with strong CYP3A inducers or moderate CYP3A inducers.</p><p>&nbsp;</p><p><u>Bile acid sequestrants</u></p><p>Avoid co-administration of bile acid sequestrants with VENCLEXTA as this may reduce the absorption of venetoclax. If a bile acid sequestrant must be used, follow the prescribing information for the bile acid sequestrant to reduce the risk for an interaction and administer VENCLEXTA at least 4-6 hours after the sequestrant.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Effects &nbsp;of &nbsp;&nbsp;VENCLEXTA on &nbsp;Other &nbsp;&nbsp;&nbsp;Drugs</u></p><p>&nbsp;</p><p><u>Warfarin</u></p><p>&nbsp;</p><p>Concomitant use of VENCLEXTA increases warfarin Cmax and AUCinf, which may increase the risk of bleeding. Closely monitor international normalized ratio (INR) in patients using warfarin concomitantly with VENCLEXTA.</p><p>&nbsp;</p><p><u>P-gp substrates</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of VENCLEXTA increases Cmax and AUCinf of P-gp substrates, which may increase toxicities of these substrates. Avoid concomitant use<em> </em>of VENCLEXTA with a P-gp substrate. If a concomitant use is unavoidable, separate dosing ofthe P-gp substrate at least 6 hours before VENCLEXTA.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p><u>&nbsp;</u></p><p><u>Risk &nbsp;Summary</u></p><p>&nbsp;</p><p>There are no available data on VENCLEXTA use in pregnant women to inform a drugassociated risk of major birth defects and miscarriage. Based on toxicity observed in mice, VENCLEXTA may cause fetal harm when administered to pregnant women. In mice, venetoclax was fetotoxic at exposures 1.2 times the human clinical exposure based on AUC at the recommended human dose of 400 mg daily. If VENCLEXTA is used during pregnancy or if the patient becomes pregnant while taking VENCLEXTA, the patient should be apprised of the potential risk to a fetus.</p><p>&nbsp;</p><p>The estimated background risk of major birth defects and miscarriage for the indicated</p><p>population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.</p><p>The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</p><p>&nbsp;</p><p><u>Data</u></p><p><em>Animal data</em></p><p>In embryo-fetal development studies, venetoclax was administered to pregnant mice and rabbits during the period of organogenesis. In mice, venetoclax was associated with increased post- implantation loss and decreased fetal body weight at 150 mg/kg/day (maternal exposures approximately 1.2 times the human AUC exposure at the recommended dose of 400 mg daily). No teratogenicity was observed in either the mouse or the rabbit.</p><p>&nbsp;</p><p><u>Lactation </u></p><p><u>&nbsp;</u></p><p><u>&nbsp;Risk &nbsp;Summary</u></p><p>&nbsp;</p><p>There are no data on the presence of VENCLEXTA in human milk, the effects of VENCLEXTA on the breastfed child, or the effects of VENCLEXTA on milk production. Venetoclax was present in the milk when administered to lactating rats <em>(see Data)</em></p><p>&nbsp;</p><p>Because many drugs are excreted in human milk and because the potential for serious adverse reactions in a breastfed child from VENCLEXTA is unknown, advise nursing women to discontinue breastfeeding during treatment with VENCLEXTA.</p><p>&nbsp;</p><p>Data</p><p><em>Animal Data</em></p><p>Venetoclax was administered (single dose; 150 mg/kg oral) to lactating rats 8 to 10 days<em> </em>parturition. Venetoclax in milk was 1.6 times lower than in plasma. Parent drug (venetoclax)<em> </em>represented the majority of the total drug-related material in milk, with trace levels of three<em> </em>metabolites.</p><p>&nbsp;</p><p><u>&nbsp;Females &nbsp;and &nbsp;Males &nbsp;of &nbsp;Reproductive &nbsp;Potential</u></p><p>&nbsp;</p><p>VENCLEXTA may cause fetal harm. <u>Pregnancy &nbsp;Testing</u></p><p>Conduct pregnancy testing in females of reproductive potential before initiation of VENCLEXTA.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>&nbsp;</p><p>Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose.</p><p>&nbsp;</p><p><u>Infertility</u></p><p>&nbsp;</p><p>Based on findings in animals, male fertility may be compromised by treatment with VENCLEXTA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of VENCLEXTA on the ability to drive and use machines have been performed.</p><p>VENCLEXTA has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following serious adverse events are discussed in greater detail in other sections of the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumor Lysis Syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia</p><p>&nbsp;</p><p>Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.</p><p><u>&nbsp;</u></p><p><u>Clinical &nbsp;&nbsp;&nbsp;&nbsp;Trial &nbsp;Experience </u><strong><u>with CLL/SLL</u></strong></p><p><u>&nbsp;</u></p><p>MURANO</p><p>The safety of VENCLEXTA in combination with rituximab (VEN+R) versus bendamustine in combination with rituximab (B+R), was evaluated in an open-label randomized study, in patients with CLL who had received at least one prior therapy.</p><p>Patients randomized to VEN+R completed the scheduled ramp-up (5 weeks) and received</p><p>VENCLEXTA 400 mg once daily in combination with rituximab for 6 cycles followed by single agent VENCLEXTA for a total of 24 months after ramp-up. Patients randomized to B+R received 6 cycles (28 days per cycle) for a total of 6 months. Details of the study treatment are described in Section 14 <em>[see Clinical Studies (14.1)]</em>.</p><p>At the time of analysis, the median duration of exposure was 22 months in the VEN+R arm compared with 6 months in the B+R arm.</p><p>In the VEN+R arm, fatal adverse reactions that occurred in the absence of disease progression and within 30 days of the last VENCLEXTA treatment and/or 90 days of last rituximab were reported in 2% (4/194) of patients. Serious adverse reactions were reported in 46% of patients in the VEN+R arm, with most frequent (&ge;5%) being pneumonia (9%).</p><p>&nbsp;</p><p>In the VEN+R arm, adverse reactions led to treatment discontinuation in 16% of patients, dose reduction in 15%, and dose interruption in 71%. In the B+R arm, adverse reactions led to treatment discontinuation in 10% of patients, dose reduction in 15%, and dose interruption in 40%. In the VEN+R arm, neutropenia led to dose interruption of VENCLEXTA in 46% of patients and discontinuation in 3%, and thrombocytopenia led to discontinuation in 3% of patients.</p><p>&nbsp;</p><p>Table 9 and Table 10 present adverse reactions and laboratory abnormalities, respectively, identified in the MURANO trial. The MURANO trial was not designed to demonstrate a statistically significant difference in adverse reaction rates for VEN+R as compared with B+R, for any specific adverse reaction or laboratory abnormality.</p><p>&nbsp;</p><p>Table 9. Common (&ge;10%) Adverse Reactions Reported with &ge;5% Higher All-Grade or &ge;2% Higher Grade &ge;3 Incidence in Patients Treated with VEN+R Compared with B+R</p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adverse Reaction by Body System</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>VENCLEXTA + Rituximab Followed by Single Agent VENCLEXTA</strong></p><p><strong>(N = 194)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Bendamustine + Rituximab</strong></p><p><strong>(N = 188)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade &ge;3</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade &ge;3(%)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Blood &amp; lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>a</sup></p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>44</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Infections &amp; infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>a</sup></p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Lower respiratory tract infection<sup>a</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>a</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tumor lysis syndrome</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>Includes multiple adverse reaction terms.</p></td></tr></tbody></table><p>Other adverse reactions (all Grades) reported in &ge;10% of patients in the VEN+R arm in MURANO, and other important adverse reactions are presented below:</p><p>&nbsp;</p><p><strong>Blood &amp; lymphatic system disorders:</strong> anemia (16%), thrombocytopenia (15%), febrile neutropenia (4%)</p><p><strong>Gastrointestinal disorders: </strong>nausea (21%), constipation (14%), abdominal pain (13%), mucositis (10%), vomiting (8%)</p><p><strong>Respiratory disorders:</strong> cough (22%)</p><p><strong>General disorders and administration site conditions:</strong> fatigue (22%), pyrexia (15%)</p><p><strong>Skin disorders:</strong> rash (13%)</p><p><strong>Nervous system and psychiatric disorders:</strong> headache (11%), insomnia (11%)</p><p><strong>Infections &amp; infestations:</strong> pneumonia (10%)</p><p>During treatment with single agent VENCLEXTA after completion of VEN+R combination treatment, the most common all grade adverse reactions (&ge;10% patients) reported were upper respiratory tract infection (21%), diarrhea (19%), neutropenia (16%), and lower respiratory tract infections (11%).The most common grade 3 or 4 adverse reaction (&ge;2% patients) were neutropenia (12%) and anemia (3%).</p><p><em>&nbsp;</em></p><p><em>Laboratory Abnormalities</em></p><p><em>&nbsp;</em></p><p>Table 10 describes common treatment-emergent laboratory abnormalities identified in the MURANO trial.</p><p><strong>&nbsp;</strong></p><p><strong>Table 10. </strong><strong>Common (&ge;10%) New or Worsening </strong><strong>Laboratory Abnormalities Occurring at </strong><strong>&ge;5% </strong><strong>(Any Grade) </strong><strong>or &ge;2% </strong><strong>(Grade 3 or 4) Higher Incidence with VEN+R Compared with B+R</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>VENCLEXTA + Rituximab</strong></p><p><strong>N=194</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Bendamustine + Rituximab</strong></p><p><strong>N=188</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory Abnormality</strong></p></td><td style="vertical-align:top"><p><strong>All Grades<sup>a</sup></strong></p><p><strong>(%)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Grade 3 or 4 </strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>All Grades<sup>a</sup></strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4 </strong></p><p><strong>(%)</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Hematology</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td colspan="2" style="vertical-align:top"><p>89</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>81</p></td><td style="vertical-align:top"><p>35</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td colspan="2" style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>55</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td colspan="2" style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>59</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Chemistry</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td colspan="2" style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphatemia</p></td><td colspan="2" style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>AST/SGOT increased</p></td><td colspan="2" style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricemia</p></td><td colspan="2" style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase increased</p></td><td colspan="2" style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Hyperbilirubinemia</p></td><td colspan="2" style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatremia</p></td><td colspan="2" style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td colspan="2" style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalemia</p></td><td colspan="2" style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Hypernatremia</p></td><td colspan="2" style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycemia</p></td><td colspan="2" style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup>Includes laboratory abnormalities that were new or worsening, or with worsening from baseline unknown.&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>New Grade 4 laboratory abnormalities reported in &ge;2% of patients treated with VEN+R included neutropenia (31%), lymphopenia (16%), leukopenia (6%), thrombocytopenia (6%), hyperuricemia (4%), hypocalcemia (2%), hypoglycemia (2%), and hypermagnesemia (2%).</p><p><strong>&nbsp;</strong></p><p><u>Monotherapy Studies (M13-982, M14-032, and M12-175)</u></p><p>The safety of single agent VENCLEXTA at the 400 mg recommended daily dose following a dose ramp-up schedule is based on pooled data from three single-arm trials (M13-982, M14-032, and M12-175). In the pooled dataset, consisting of 352 patients with previously treated CLL or SLL, the median age was 66 years (range: 28 to 85 years), 93% were white, and 68% were male. The median number of prior therapies was 3 (range: 0 to 15). The median duration of treatment with VENCLEXTA at the time of data analysis was 14.5 months (range: 0 to 50 months). Fifty-two percent of patients received VENCLEXTA for more than 60 weeks.</p><p>Fatal adverse reactions that occurred in the absence of disease progression and within 30 days of venetoclax treatment were reported in 2% of patients in the VENCLEXTA monotherapy studies, most commonly (2 patients) from septic shock. Serious adverse reactions were reported in 52% of patients, with the most frequent (&ge;5%) being pneumonia (9%), febrile neutropenia (5%), and sepsis (5%).</p><p>Adverse reactions led to treatment discontinuation in 9% of patients, dose reduction in 13%, and dose interruption in 36%. The most frequent adverse reactions leading to drug discontinuation were thrombocytopenia and autoimmune hemolytic anemia. The most frequent adverse reaction (&ge;5%) leading to dose reductions or interruptions was neutropenia (8%).</p><p>Adverse reactions identified in these trials of single-agent VENCLEXTA are presented in Table 11</p><p><strong>&nbsp;</strong></p><p>Table 11. Adverse Reactions Reported in &ge;10% (Any Grade) or &ge;5% (Grade &ge;3) of Patients with Previously Treated CLL/SLL (VENCLEXTA Monotherapy)</p><p dir="LTR">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR"><strong>Body System</strong></p></td><td style="vertical-align:top"><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR"><strong>Adverse Reaction</strong></p></td><td><p dir="LTR"><strong>Any Grade (%)<br />N=352</strong></p></td><td><p dir="LTR"><strong>Grade &ge;3 (%)<br />N=352</strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p dir="LTR">Blood and lymphatic system disorders</p></td><td><p dir="LTR">Neutropenia<sup>a</sup></p></td><td><p dir="LTR">50</p></td><td><p dir="LTR">45</p></td></tr><tr><td><p dir="LTR">Anemia<sup>a</sup></p></td><td><p dir="LTR">33</p></td><td><p dir="LTR">18</p></td></tr><tr><td><p dir="LTR">Thrombocytopenia<sup>a</sup></p></td><td><p dir="LTR">29</p></td><td><p dir="LTR">20</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Lymphopenia<sup>a</sup></p></td><td><p dir="LTR">11</p></td><td><p dir="LTR">7</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Febrile neutropenia</p></td><td><p dir="LTR">6</p></td><td><p dir="LTR">6</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p dir="LTR">Gastrointestinal disorders</p></td><td style="vertical-align:top"><p dir="LTR">Diarrhea</p></td><td><p dir="LTR">43</p></td><td><p dir="LTR">3</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Nausea</p></td><td><p dir="LTR">42</p></td><td><p dir="LTR">1</p></td></tr><tr><td><p dir="LTR">Abdominal pain<sup>a</sup></p></td><td><p dir="LTR">18</p></td><td><p dir="LTR">3</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Vomiting</p></td><td><p dir="LTR">16</p></td><td><p dir="LTR">1</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Constipation</p></td><td><p dir="LTR">16</p></td><td><p dir="LTR">&lt;1</p></td></tr><tr><td><p dir="LTR">Mucositis<sup>a</sup></p></td><td><p dir="LTR">13</p></td><td><p dir="LTR">&lt;1</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p dir="LTR">General disorders and administration site conditions</p></td><td><p dir="LTR">Fatigue<sup>a</sup></p></td><td><p dir="LTR">32</p></td><td><p dir="LTR">4</p></td></tr><tr><td><p dir="LTR">Edema<sup>a</sup></p></td><td><p dir="LTR">22</p></td><td><p dir="LTR">2</p></td></tr><tr><td><p dir="LTR">Pyrexia</p></td><td><p dir="LTR">18</p></td><td style="vertical-align:top"><p dir="LTR">&lt;1</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR"><s>Peripheral edema</s></p></td><td style="vertical-align:top"><p dir="LTR"><s>11</s></p></td><td style="vertical-align:top"><p dir="LTR"><s>&lt;1</s></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p dir="LTR">Infections and infestations</p></td><td><p dir="LTR">Upper respiratory tract infection<sup>a</sup></p></td><td><p dir="LTR">36</p></td><td><p dir="LTR">1</p></td></tr><tr><td><p dir="LTR">Pneumonia<sup>a</sup></p></td><td><p dir="LTR">14</p></td><td><p dir="LTR">8</p></td></tr><tr><td><p dir="LTR">Lower respiratory tract infection<sup>a</sup></p></td><td><p dir="LTR">11</p></td><td><p dir="LTR">2</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR"><s>Metabolism and nutrition disorders</s></p></td><td style="vertical-align:top"><p dir="LTR"><s>Hypokalemia</s></p></td><td style="vertical-align:top"><p dir="LTR"><s>12</s></p></td><td style="vertical-align:top"><p dir="LTR"><s>4</s></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="LTR">Musculoskeletal and connective tissue disorders</p></td><td><p dir="LTR">Musculoskeletal pain<sup>a</sup></p></td><td><p dir="LTR">29</p></td><td><p dir="LTR">2</p></td></tr><tr><td><p dir="LTR">Arthralgia</p></td><td><p dir="LTR">12</p></td><td><p dir="LTR">&lt;1</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="LTR">&nbsp;</p><p dir="LTR">Nervous system disorders</p></td><td><p dir="LTR">Headache</p></td><td><p dir="LTR">18</p></td><td><p dir="LTR">&lt;1</p></td></tr><tr><td><p dir="LTR">Dizziness<sup>a</sup></p></td><td><p dir="LTR">14</p></td><td><p dir="LTR">0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="LTR">Respiratory, thoracic, and mediastinal disorders</p></td><td><p dir="LTR">Cough<sup>a</sup></p></td><td><p dir="LTR">22</p></td><td><p dir="LTR">0</p></td></tr><tr><td><p dir="LTR">Dyspnea<sup>a</sup></p></td><td><p dir="LTR">13</p></td><td><p dir="LTR">1</p></td></tr><tr><td><p dir="LTR">Skin and subcutaneous tissue disorders</p></td><td><p dir="LTR">Rash<sup>a</sup></p></td><td><p dir="LTR">18</p></td><td><p dir="LTR">&lt;1</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p dir="LTR">Adverse Reactions graded using NCI Common Terminology Criteria for Adverse Events version 4.0.<br /><sup>a</sup>Includes multiple adverse reaction terms</p></td></tr></tbody></table><p dir="LTR">&nbsp;</p><p><em>Laboratory Abnormalities</em></p><p>Table 12 describes common laboratory abnormalities reported throughout treatment that were new or worsening from baseline. The most common (&gt;5%) Grade 4 laboratory abnormalities observed with VENCLEXTA monotherapy were hematologic laboratory abnormalities, including neutropenia (33%), leukopenia (11%), thrombocytopenia (15%), and lymphopenia (9%).</p><p>&nbsp;</p><p>Table 12. New or Worsening Laboratory Abnormalities with VENCLEXTA Monotherapy (&ge;40% Any Grade or &ge;10% Grade 3 or 4)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:75%"><tbody><tr><td style="vertical-align:bottom"><p><strong>Laboratory Abnormality</strong></p></td><td style="vertical-align:bottom"><p><strong>All Grades<sup>a</sup></strong></p><p><strong>(%)</strong></p><p><strong>N=352</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p><p><strong>N=352</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Hematology</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Leukopenia</p></td><td style="vertical-align:top"><p>89</p></td><td style="vertical-align:top"><p>42</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Neutropenia</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>63</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Lymphopenia</p></td><td style="vertical-align:top"><p>74</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Chemistry</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalemia</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>AST increased</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminemia</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphatemia</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatremia</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>Includes laboratory abnormalities that were new or worsening, or worsening from baseline unknown.&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Important Adverse Reactions</u></p><p>&nbsp;</p><p><em>Tumor Lysis Syndrome</em></p><p>&nbsp;</p><p>Tumor lysis syndrome is an important identified risk when initiating VENCLEXTA.</p><p><s>&nbsp;</s></p><p><em>MURANO</em></p><p>In the open-label randomized phase 3 study, the incidence of TLS was 3% (6/194) in patients</p><p>treated with VEN+R. After 77/389 patients were enrolled in the study, the protocol was amended</p><p>to incorporate the current TLS prophylaxis and monitoring measures described in sections Dosage And Administration.</p><p>All events of TLS occurred during the VENCLEXTA ramp-up period and were resolved within two days. All six patients completed the ramp-up and reached the recommended daily dose of 400 mg of VENCLEXTA. No clinical</p><p>TLS was observed in patients who followed the current 5-week ramp-up schedule and TLS prophylaxis and monitoring measures described in Dosage And Administration. Rates of laboratory abnormalities relevant to TLS for patients treated with VEN+R are presented in Table 10.</p><p><em><u>Monotherapy Studies (M13-982 and M14-032)</u></em></p><p><s>&nbsp;</s></p><p>&nbsp;</p><p>In 168 patients with CLL treated according to recommendations described in Dosage And Administration , the rate of TLS was 62%. All events either met laboratory TLS criteria (laboratory abnormalities that met &ge;2 of the following within 24 hours of each other: potassium &gt;6 mmol/L, uric acid &gt;476 &micro;mol/L, calcium &lt;1.75 mmol/L, or phosphorus &gt;1.5 mmol/L); or were reported as TLS events. The events occurred in patients who had a lymph node(s) &ge;5 cm and/or ALC &ge;25 x 109/L. All events resolved within 5 days. No TLS with clinical consequences such as acute renal failure, cardiac arrhythmias or sudden death and/or seizures was observed in these patients. All patients had CLcr &ge;50 mL/min. Laboratory abnormalities relevant to TLS were hyperkalemia (17% all Grades, 1% Grade &ge;3), hyperphosphatemia (14% all Grades, 2% Grade &ge;3), hypocalcemia (16% all Grades, 2% Grade &ge;3), and hyperuricemia (10% all Grades, &lt;1% Grade &ge;3).</p><p>In the initial Phase 1 dose-finding trials, which had shorter (2-3 week) ramp-up phase and higher starting doses, the incidence of TLS was 13% (10/77; 5 laboratory TLS, 5 clinical TLS), including 2 fatal events and 3 events of acute renal failure, 1 requiring dialysis. After this experience, TLS risk assessment, dosing regimen, TLS prophylaxis and monitoring measures were revised.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong><u>Clinical Trial Experience with AML</u></strong></p><p>&nbsp;</p><p>The safety of VENCLEXTA (400 mg daily dose) in combination with azacitidine (n=67) or decitabine (n= 13) and VENCLEXTA (600 mg daily dose) in combination with low-dose cytarabine (n= 61) is based on two non-randomized trials of patients with newly-diagnosed AML. The median duration of exposure for patients taking VENCLEXTA in combination with azacitidine and decitabine was 6.5 months (range: 0.1 to 31.9 months) and 8.4 months (range: 0.5 to 22.3 months), respectively. The median duration of exposure for patients taking VENCLEXTA in combination with low dose cytarabine was 3.9 months (range: 0.2 to 29.2 months).</p><p>&nbsp;</p><p><u>VENCLEXTA in Combination with Azacitidine or Decitabine</u></p><p>&nbsp;</p><p>Azacitidine</p><p>The most common adverse reactions (&ge;30%) of any grade were nausea, diarrhea, constipation, neutropenia, thrombocytopenia, hemorrhage, peripheral edema, vomiting, fatigue, febrile neutropenia, rash, and anemia.</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 75% of patients. The most frequent serious adverse reactions (&ge;5%) were febrile neutropenia, pneumonia (excluding fungal), sepsis (excluding fungal), respiratory failure, and multiple organ dysfunction syndrome.</p><p>&nbsp;</p><p>The incidence of fatal adverse drug reactions was 1.5% within 30 days of starting treatment. No reaction had an incidence of &ge;2%.</p><p>&nbsp;</p><p>Discontinuations due to adverse reactions occurred in 21% of patients. The most frequent adverse reactions leading to drug discontinuation (&ge;2%) were febrile neutropenia and pneumonia (excluding fungal).</p><p>&nbsp;</p><p>Dosage interruptions due to adverse reactions occurred in 61% of patients. The most frequent adverse reactions leading to dose interruption (&ge;5%) were neutropenia, febrile neutropenia, and pneumonia (excluding fungal).</p><p>&nbsp;</p><p>Dosage reductions due to adverse reactions occurred in 12% of patients. The most frequent adverse reaction leading to dose reduction (&ge;5%) was neutropenia.</p><p>&nbsp;</p><p>Decitabine</p><p>The most common adverse reactions (&ge;30%) of any grade were febrile neutropenia, constipation, fatigue, thrombocytopenia, abdominal pain, dizziness, hemorrhage, nausea, pneumonia hypotension, myalgia, oropharyngeal pain, peripheral edema, pyrexia, and rash.</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 85% of patients. The most frequent serious adverse reactions (&ge;5%) were febrile neutropenia, sepsis (excluding fungal), pneumonia (excluding fungal), diarrhea, fatigue, cellulitis, and localized infection.</p><p>&nbsp;</p><p>One (8%) fatal adverse drug reaction of bacteremia occurred within 30 days of starting treatment.</p><p>&nbsp;</p><p>Discontinuations due to adverse reactions occurred in 38% of patients. The most frequent adverse reaction leading to drug discontinuation (&ge;5%) was pneumonia (excluding fungal).</p><p>&nbsp;</p><p>Dosage interruptions due to adverse reactions occurred in 62% of patients. The most frequent adverse reactions leading to dose interruption (&ge;5%) were febrile neutropenia, neutropenia, and pneumonia (excluding fungal).</p><p>&nbsp;</p><p>&nbsp;</p><p>Dosage reductions due to adverse reactions occurred in 15% of patients. The most frequent adverse reaction leading to dose reduction (&ge;5%) was neutropenia.</p><p>&nbsp;</p><p>Adverse reactions reported in patients with newly-diagnosed AML using VENCLEXTA in combination with azacitidine or decitabine are presented in Table 13.</p><p>&nbsp;</p><p>Table 13. Adverse Reactions Reported in &ge;30% (Any Grade) or &ge;5% (Grade &ge;3) of Patients with AML Treated with VENCLEXTA in Combination with Azacitidine or Decitabine</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Body System</strong></p></td><td rowspan="2"><p><strong>Adverse Reaction</strong></p></td><td colspan="2"><p><strong>VENCLEXTA in Combination with Azacitidine</strong></p></td><td colspan="2"><p><strong>VENCLEXTA in Combination with Decitabine</strong></p></td></tr><tr><td><p><strong>Any Grade (%)</strong><br /><strong>N = 67</strong></p></td><td><p><strong>Grade &ge;3 (%)</strong><br /><strong>N = 67</strong></p></td><td><p><strong>Any Grade (%) </strong><br /><strong>N = 13</strong></p></td><td><p><strong>Grade &ge;3 (%)</strong><br /><strong>N = 13 </strong></p></td></tr><tr><td rowspan="4"><p>Blood and lymphatic system disorders</p></td><td><p>Thrombocytopenia<sup>a</sup></p></td><td><p>49</p></td><td><p>45</p></td><td><p>54</p></td><td><p>54</p></td></tr><tr><td><p>Neutropenia<sup>a</sup></p></td><td><p>49</p></td><td><p>49</p></td><td><p>38</p></td><td><p>38</p></td></tr><tr><td><p>Febrile neutropenia</p></td><td><p>36</p></td><td><p>36</p></td><td><p>69</p></td><td><p>69</p></td></tr><tr><td><p>Anemia<sup>a</sup></p></td><td><p>30</p></td><td><p>30</p></td><td><p>15</p></td><td><p>15</p></td></tr><tr><td rowspan="5"><p>Gastrointestinal disorders</p></td><td><p>Nausea</p></td><td><p>58</p></td><td><p>1</p></td><td><p>46</p></td><td><p>0</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>54</p></td><td><p>3</p></td><td><p>38</p></td><td><p>8</p></td></tr><tr><td><p>Constipation</p></td><td><p>49</p></td><td><p>3</p></td><td><p>62</p></td><td><p>0</p></td></tr><tr><td><p>Vomiting<sup>a</sup></p></td><td><p>40</p></td><td><p>0</p></td><td><p>23</p></td><td><p>0</p></td></tr><tr><td><p>Abdominal pain<sup>a</sup></p></td><td><p>22</p></td><td><p>4</p></td><td><p>46</p></td><td><p>0</p></td></tr><tr><td rowspan="5"><p>General disorders and<br />administration site conditions</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>Peripheral edema<sup>a</sup></p></td><td><p>46</p></td><td><p>1</p></td><td><p>31</p></td><td><p>0</p></td></tr><tr><td><p>Fatigue<sup>a</sup></p></td><td><p>36</p></td><td><p>7</p></td><td><p>62</p></td><td><p>15</p></td></tr><tr><td><p>Pyrexia</p></td><td><p>21</p></td><td><p>3</p></td><td><p>31</p></td><td><p>0</p></td></tr><tr><td><p>Cachexia</p></td><td><p>0</p></td><td><p>0</p></td><td><p>8</p></td><td><p>8</p></td></tr><tr><td><p>Multiple organ dysfunction syndrome</p></td><td><p>6</p></td><td><p>6</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td rowspan="5"><p>Infections and infestations</p></td><td><p>Pneumonia (excluding fungal)<sup>a</sup></p></td><td><p>27</p></td><td><p>25</p></td><td><p>46</p></td><td><p>31</p></td></tr><tr><td><p>Sepsis (excluding fungal)<sup>a</sup></p></td><td><p>13</p></td><td><p>13</p></td><td><p>46</p></td><td><p>46</p></td></tr><tr><td><p>Urinary tract infection</p></td><td><p>16</p></td><td><p>6</p></td><td><p>23</p></td><td><p>0</p></td></tr><tr><td><p>Cellulitis</p></td><td><p>6</p></td><td><p>0</p></td><td><p>15</p></td><td><p>8</p></td></tr><tr><td><p>Localized infection</p></td><td><p>0</p></td><td><p>0</p></td><td><p>8</p></td><td><p>8</p></td></tr><tr><td rowspan="2"><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Back pain</p></td><td><p>15</p></td><td><p>0</p></td><td><p>31</p></td><td><p>0</p></td></tr><tr><td><p>Myalgia<sup>a</sup></p></td><td><p>10</p></td><td><p>0</p></td><td><p>31</p></td><td><p>0</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Dizziness<sup>a</sup></p></td><td><p>28</p></td><td><p>1</p></td><td><p>46</p></td><td><p>0</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Rash<sup>a</sup></p></td><td><p>33</p></td><td><p>1</p></td><td><p>31</p></td><td><p>0</p></td></tr><tr><td rowspan="3"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Cough<sup>a</sup></p></td><td><p>25</p></td><td><p>0</p></td><td><p>38</p></td><td><p>0</p></td></tr><tr><td><p>Hypoxia</p></td><td><p>18</p></td><td><p>6</p></td><td><p>15</p></td><td><p>0</p></td></tr><tr><td><p>Oropharyngeal pain</p></td><td><p>9</p></td><td><p>0</p></td><td><p>31</p></td><td><p>0</p></td></tr><tr><td rowspan="3"><p>Vascular disorders</p></td><td><p>Hemorrhage<sup>a</sup></p></td><td><p>46</p></td><td><p>7</p></td><td><p>46</p></td><td><p>0</p></td></tr><tr><td><p>Hypotension<sup>a</sup></p></td><td><p>21</p></td><td><p>6</p></td><td><p>31</p></td><td><p>0</p></td></tr><tr><td><p>Hypertension</p></td><td><p>12</p></td><td><p>7</p></td><td><p>15</p></td><td><p>8</p></td></tr><tr><td colspan="6"><p>Adverse Reactions graded using NCI Common Terminology Criteria for Adverse Events version 4.0.<br /><sup>a</sup>Includes multiple adverse reaction terms.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Laboratory Abnormalities</em></p><p>Table 14 describes common laboratory abnormalities reported throughout treatment that were new or worsening from baseline.</p><p>&nbsp;</p><p>Table 14. New or Worsening Laboratory Abnormalities with VENCLEXTA Reported in &ge;40% (Any Grade) or &ge;10% (Grade 3 or 4) of Patients with AML Treated with VENCLEXTA in Combination with Azacitidine or Decitabine</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td rowspan="2"><p><strong>Laboratory Abnormality</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>VENCLEXTA in Combination with Azacitidine</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>VENCLEXTA in Combination with Decitabine</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Any Grade<sup>a</sup></strong></p><p><strong>(%)</strong></p><p><strong>N = 67 </strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4<sup>a</sup></strong></p><p><strong>(%)</strong></p><p><strong>N = 67 </strong></p></td><td style="vertical-align:top"><p><strong>Any Grade<sup>a</sup>(%) </strong><br /><strong>N = 13</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4<sup>a</sup> (%)</strong><br /><strong>N = 13</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Hematology</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>98</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>91</p></td><td style="vertical-align:top"><p>78</p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>83</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>88</p></td><td style="vertical-align:top"><p>73</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>92</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>69</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Chemistry</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Hypoalbuminemia</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatremia</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphatemia</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Hyperbilirubinemia</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesemia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>Includes laboratory abnormalities that were new or worsening, or worsening from baseline unknown.</p></td></tr></tbody></table><p>&nbsp;</p><p>VENCLEXTA in Combination with Low-Dose Cytarabine</p><p>The most common adverse reactions (&ge;30%) of any grade were nausea, thrombocytopenia, hemorrhage, febrile neutropenia, neutropenia, diarrhea, fatigue, constipation, and dyspnea.</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 95% of patients. The most frequent serious adverse reactions (&ge;5%) were febrile neutropenia, sepsis (excluding fungal), hemorrhage, pneumonia (excluding fungal), and device-related infection.</p><p>&nbsp;</p><p>The incidence of fatal adverse drug reactions was 4.9% within 30 days of starting treatment with no reaction having an incidence of &ge;2%.</p><p>&nbsp;</p><p>Discontinuations due to adverse reactions occurred in 33% of patients. The most frequent adverse reactions leading to drug discontinuation (&ge;2%) were hemorrhage and sepsis (excluding fungal).</p><p>&nbsp;</p><p>Dosage interruptions due to adverse reactions occurred in 52% of patients. The most frequent adverse reactions leading to dose interruption (&ge;5%) were thrombocytopenia, neutropenia, and febrile neutropenia.</p><p>&nbsp;</p><p>Dosage reductions due to adverse reactions occurred in 8% of patients. The most frequent adverse reaction leading to dose reduction (&ge;2%) was thrombocytopenia.</p><p>&nbsp;</p><p>Adverse reactions reported in patients with newly-diagnosed AML receiving VENCLEXTA in combination with low-dose cytarabine are presented in Table 15.</p><p>&nbsp;</p><p>Table 15. Adverse Reactions Reported in &ge;30% (Any Grade) or &ge;5% (Grade &ge;3) of Patients with AML Treated with VENCLEXTA in Combination with Low-Dose Cytarabine.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Body System</strong></p></td><td><p><strong>Adverse Reaction</strong></p></td><td><p><strong>Any Grade (%)</strong><br /><strong>N = 61&nbsp; </strong></p></td><td><p><strong>Grade &ge;3 (%)</strong><br /><strong>N = 61&nbsp; </strong></p></td></tr><tr><td rowspan="4"><p>Blood and lymphatic system disorders</p></td><td><p>Thrombocytopenia<sup>a</sup></p></td><td><p>59</p></td><td><p>59</p></td></tr><tr><td><p>Neutropenia<sup>a</sup></p></td><td><p>46</p></td><td><p>46</p></td></tr><tr><td><p>Febrile neutropenia</p></td><td><p>46</p></td><td><p>44</p></td></tr><tr><td><p>Anemia<sup>a</sup></p></td><td><p>26</p></td><td><p>26</p></td></tr><tr><td rowspan="3"><p>Gastrointestinal disorders</p></td><td><p>Nausea</p></td><td><p>64</p></td><td><p>2</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>44</p></td><td><p>3</p></td></tr><tr><td><p>Constipation</p></td><td><p>33</p></td><td><p>0</p></td></tr><tr><td><p>General disorders and<br />administration site conditions</p></td><td><p>Fatigue<sup>a</sup></p></td><td><p>44</p></td><td><p>10</p></td></tr><tr><td rowspan="4"><p>Infections and infestations</p></td><td><p>Sepsis<sup>a</sup></p></td><td><p>20</p></td><td><p>18</p></td></tr><tr><td><p>Pneumonia<sup>a</sup></p></td><td><p>18</p></td><td><p>16</p></td></tr><tr><td><p>Device related infection</p></td><td><p>13</p></td><td><p>11</p></td></tr><tr><td><p>Urinary tract infection</p></td><td><p>8</p></td><td><p>7</p></td></tr><tr><td><p>Metabolic and nutritional disorders</p></td><td><p>Decreased appetite<sup>a</sup></p></td><td><p>28</p></td><td><p>7</p></td></tr><tr><td><p>Respiratory disorders</p></td><td><p>Dyspnea<sup>a</sup></p></td><td><p>31</p></td><td><p>3</p></td></tr><tr><td rowspan="3"><p>Vascular disorders</p></td><td><p>Hemorrhage<sup>a</sup></p></td><td><p>49</p></td><td><p>15</p></td></tr><tr><td><p>Hypotension<sup>a</sup></p></td><td><p>21</p></td><td><p>7</p></td></tr><tr><td><p>Hypertension</p></td><td><p>15</p></td><td><p>8</p></td></tr><tr><td colspan="4"><p>Adverse Reactions graded using NCI Common Terminology Criteria for Adverse Events version 4.0.<br /><sup>a</sup>Includes multiple adverse reaction terms.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Laboratory Abnormalities</em></p><p>&nbsp;</p><p>Table 16 describes common laboratory abnormalities reported throughout treatment that were new or worsening from baseline.</p><p><strong>&nbsp;</strong></p><p>Table 16. New or Worsening Laboratory Abnormalities with VENCLEXTA Reported in &ge;40% (Any Grade) or &ge;10% (Grade 3 or 4) of Patients with AML Treated with VENCLEXTA in Combination with Low-Dose Cytarabine</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:91%"><tbody><tr><td><p><strong>Laboratory Abnormality</strong></p></td><td style="vertical-align:top"><p><strong>All Grades<sup>a</sup></strong></p><p><strong>(%)</strong></p><p><strong>N = 61&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4<sup>a</sup></strong></p><p><strong>(%)</strong></p><p><strong>N = 61&nbsp; </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Hematology</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>96</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>96</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>96</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>66</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>59</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Chemistry</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Hypocalcemia</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatremia</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Hyperbilirubinemia</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminemia</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphatemia</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesemia</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Blood bicarbonate decreased</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>Includes laboratory abnormalities that were new or worsening, or worsening from baseline unknown.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Tumor Lysis Syndrome</em></p><p>Tumor lysis syndrome is an important risk when initiating treatment in patients with AML. The incidence of TLS was 3% (2/61) with VENCLEXTA in combination with low-dose cytarabine with implementation of dose ramp-up schedule in addition to standard prophylaxis and monitoring measures. All events were laboratory TLS, and all patients were able to reach the target dose.</p><p>&nbsp;</p><p>To report any side effects for <u>VENCLEXTA</u> please contact:</p><p><strong><u>Saudi Arabia</u></strong></p><p>The National Pharmacovigilance and Drug Safety Center - Saudi food and drug authority</p><p>Fax: +966-11-205-7662</p><p>Call NPC at&nbsp; +966-11-2038222,</p><p>Ext: 2317-2356-2353-2354-2334</p><p>Toll free phone: 8002490000 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc<u>&nbsp;</u></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote for VENCLEXTA. For patients who experience overdose, closely monitor and provide appropriate supportive treatment; during ramp-up phase interrupt VENCLEXTA and monitor carefully for signs and symptoms of TLS along with other toxicities. Based on Venetoclax large volume of distribution and extensive protein binding, dialysis is unlikely to result in significant removal of Venetoclax.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents, ATC code: not yet assigned</p><p>&nbsp;</p><p><u>Mechanism &nbsp;of &nbsp;action</u></p><p>&nbsp;</p><p>Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti- apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL and AML cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.</p><p>&nbsp;</p><p><u>Pharmacodynamic &nbsp;&nbsp;effects</u></p><p><u>&nbsp;</u></p><p>Based on the exposure response analyses for efficacy, a relationship between drug exposure and a greater likelihood of response was observed in clinical studies in patients with CLL/SLL, and in patients with AML. Based on the exposure response analyses for safety, a relationship between drug exposure and a greater likelihood of some safety events was observed in clinical studies in patients with AML. No exposure-safety relationship was observed in patients with CLL/SLL at doses up to 1200 mg given as monotherapy and up to 600 mg given in combination with rituximab.</p><p>&nbsp;</p><p><u>Cardiac &nbsp;Electrophysiology</u></p><p>&nbsp;</p><p>The effect of multiple doses of VENCLEXTA up to 1200 mg once daily (2 times the maximum</p><p>approved recommended dosage) on the QTc interval was evaluated in an open-label, single-arm study in 176 patients with previously treated hematologic malignancies. VENCLEXTA had no large effect on QTc interval (i.e., &gt; 20 ms) and there was no relationship between Venetoclax exposure and change in QTc interval.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venetoclax mean (&plusmn; standard deviation) steady state Cmax was 2.1 &plusmn; 1.1 mcg/mL and AUC0-24 was 32.8 &plusmn; 16.9 mcg&bull;h/mL following administration of 400 mg once daily with a low-fat meal.Venetoclax steady state AUC increased proportionally over the dose range of 150 to 800 mg (0.25 to 1.33 times the maximum approved recommended dosage). The pharmacokinetics of venetoclax does not change over time.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><s>&nbsp;</s></p><p>Maximum plasma concentration of venetoclax was reached 5 to 8 hours following multiple oral administration under fed conditions.</p><p>&nbsp;</p><p><em>Effect of food</em></p><p>&nbsp;</p><p>Administration with a low-fat meal (approximately 512 kilocalories, 25% fat calories, 60% carbohydrate calories, and 15% protein calories) increased venetoclax exposure by approximately 3.4-fold and administration with a high-fat meal (approximately 753 kilocalories, 55% fat calories, 28% carbohydrate calories, and 17% protein calories) increased Venetoclax exposure by 5.1- to 5.3-fold compared with fasting conditions.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Venetoclax is highly bound to human plasma protein with unbound fraction in plasma &lt;0.01 across a concentration range of 1-30 micromolar (0.87-26 mcg/mL). The mean blood-to-plasma ratio was 0.57. The apparent volume of distribution (Vdss/F) of venetoclax ranged from 256-321 L in patients.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Metabolism</u></p><p>&nbsp;</p><p>Venetoclax is predominantly metabolized by CYP3A <em>in vitro</em>. The major metabolite identified in plasma, M27, has an inhibitory activity against BCL-2 that is at least 58-fold lower than venetoclax <em>in vitro </em>and its AUC represented 80% of the parent AUC.</p><p><u>Elimination</u></p><p>&nbsp;</p><p>&nbsp;</p><p>The terminal elimination half-life of venetoclax was approximately 26 hours.</p><p><u>&nbsp;</u></p><p><u>Excretion</u></p><p>&nbsp;</p><p>After single oral dose of radiolabeled [14C]-venetoclax 200 mg to healthy subjects, &gt; 99.9% of the dose was recovered in feces (20.8% as unchanged) and &lt; 0.1% in urine within 9 days.</p><p>&nbsp;</p><p><u>Special &nbsp;Populations</u></p><p><s>&nbsp;</s></p><p>No clinically significant differences in the pharmacokinetics of venetoclax were observed based on age (19 to 90 years), sex, race (White, Black, Asians, and Others), weight, mild to moderate renal impairment (CLcr 30 to 89 mL/min, calculated by Cockcroft-Gault), or mild to moderate hepatic impairment (normal total bilirubin and aspartate transaminase (AST) &gt; upper limit of normal (ULN) or total bilirubin 1 to 3 times ULN). The effect of severe renal impairment (CLcr &lt; 30 mL/min), dialysis, or severe hepatic impairment (total bilirubin &gt; 3 times ULN) on venetoclax pharmacokinetics is unknown.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Renal &nbsp;Impairment</u></em></p><p>&nbsp;</p><p>Patients with reduced renal function (CrCl &lt;80 mL/min) are at increased risk of TLS. These patients may require more intensive prophylaxis and monitoring to reduce the risk of TLS when initiating treatment with VENCLEXTA.</p><p>&nbsp;</p><p>No specific clinical trials have been conducted in subjects with renal impairment. Less than 0.1% of radioactive VENCLEXTA dose was detected in urine. No dose adjustment is needed for patients with mild or moderate renal impairment (CrCl &ge;30 mL/min) based on results of the population pharmacokinetic analysis. A recommended dose has not been determined for patients with severe renal impairment (CrCl &lt;30 mL/min) or patients on dialysis.</p><p>&nbsp;</p><p><em><u>Hepatic &nbsp;Impairment</u></em></p><p>&nbsp;</p><p>No specific clinical trials have been conducted in subjects with hepatic impairment, however human mass balance study showed that venetoclax undergoes hepatic elimination. Although no dose adjustment is recommended in patients with mild or moderate hepatic impairment based on results of the population pharmacokinetic analysis, a trend for increased adverse events was observed in patients with moderate hepatic impairment; monitor these patients more closely for signs of toxicity during the initiation and dose ramp-up phase. A recommended dose has not been determined for patients with severe hepatic impairment.</p><p>&nbsp;</p><p><u>Drug &nbsp;Interactions studies</u></p><p><em>&nbsp;</em></p><p><em>Clinical Studies</em></p><p>No clinically significant differences in venetoclax pharmacokinetics were observed when coadministered with azacitidine, azithromycin, cytarabine, decitabine, gastric acid reducing agents, or rituximab.</p><p>&nbsp;</p><p><em>Ketoconazole</em></p><p>&nbsp;</p><p>Concomitant use of ketoconazole (a strong CYP3A, P-gp and BCRP inhibitor) 400 mg once daily for 7 days increased venetoclax Cmax by 130% and AUCinf by 540%</p><p><em>Ritonavir</em></p><p>Concomitant use of ritonavir (a strong CYP3A, P-gp and OATP1B1/B3 inhibitor) 50 mg once daily for 14 days increased venetoclax Cmax by 140% and AUC by 690%.</p><p>&nbsp;</p><p><em>Posaconazole</em></p><p>Concomitant use of posaconazole (a strong CYP3A and P-gp inhibitor) 300 mg with Venetoclax 50 mg and 100 mg for 7 days resulted in 61% and 86% higher venetoclax Cmax, respectively, compared with venetoclax 400 mg administered alone. The venetoclax AUC24 was 90% and 144% higher, respectively.</p><p>&nbsp;</p><p><em>Rifampin </em></p><p><s>&nbsp;</s></p><p>Concomitant use of a single dose of rifampin (an OATP1B1/1B3 and P-gp inhibitor) 600 mg increased venetoclax Cmax by 106% and AUCinf by 78%. Concomitant use of multiple doses of rifampin (as a strong CYP3A inducer) 600 mg once daily for 13 days decreased venetoclax Cmax by 42% and AUCinf by 71%.</p><p>&nbsp;</p><p><em>Warfarin</em></p><p>&nbsp;</p><p>Concomitant use of a single 400 mg dose of venetoclax with 5 mg warfarin resulted in 18% to 28% increase in Cmax and AUC&infin; of R-warfarin and S-warfarin</p><p><em>Digoxin</em></p><p><sub>&nbsp;</sub></p><p>Concomitant use of a single dose of venetoclax 100 mg with digoxin (a P-gp substrate) 0.5 mg increased digoxin Cmax by 35% and AUCinf by 9%</p><p>&nbsp;</p><p><em><u>In Vitro &nbsp;</u></em><u>Studies</u></p><p><s>&nbsp;</s></p><p>Venetoclax is not an inhibitor or inducer of CYP1A2, CYP2B6, CYP2C19 CYP2D6 or</p><p>CYP3A4. Venetoclax is a weak inhibitor of CYP2C8, CYP2C9, and UGT1A1.</p><p>Venetoclax is not an inhibitor of UGT1A4, UGT1A6, UGT1A9, or UGT2B7.</p><p>Venetoclax is an inhibitor and substrate of P-gp and BCRP and weak inhibitor of OATP1B1.</p><p>Venetoclax is not an inhibitor of OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, or MATE2K.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, &nbsp;Mutagenesis, &nbsp;Impairment &nbsp;of &nbsp;Fertility</u></p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with venetoclax.</p><p>&nbsp;</p><p>Venetoclax was not mutagenic in an <em>in vitro </em>bacterial mutagenicity (Ames) assay, did not induce numerical or structural aberrations in an <em>in vitro </em>chromosome aberration assay using human peripheral blood lymphocytes, and was not clastogenic in an <em>in vivo </em>mouse bone marrow micronucleus assay at doses up to 835 mg/kg. The M27 metabolite was negative for genotoxic activity in <em>in vitro </em>Ames and chromosome aberration assays.</p><p>&nbsp;</p><p>Fertility and early embryonic development studies were conducted in male and female mice. These studies evaluate mating, fertilization, and embryonic development through implantation. There were no effects of venetoclax on estrus cycles, mating, fertility, corpora lutea, uterine implants or live embryos per litter at dosages up to 600 mg/kg/day. However, a risk to human male fertility exists based on testicular toxicity (germ cell loss) observed in dogs at exposures as low as 0.5 times the human AUC exposure at the recommend dose.</p><p>&nbsp;</p><p><u>Animal &nbsp;Toxicology &nbsp;and / or &nbsp;Pharmacology</u></p><p>&nbsp;</p><p>In dogs, venetoclax caused single-cell necrosis in various tissues, including the gallbladder, exocrine pancreas, and stomach with no evidence of disruption of tissue integrity or organ dysfunction; these findings were minimal to mild in magnitude. Following a 4-week dosing period and subsequent 4- week recovery period, minimal single-cell necrosis was still present in some tissues and reversibility has not been assessed following longer periods of dosing or recovery.</p><p>In addition, after approximately 3 months of daily dosing in dogs, venetoclax caused progressive white discoloration of the hair coat, due to loss of melanin pigment.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>CLINICAL STUDIES</strong></p><p><strong>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</strong></p><p><strong>&nbsp;</strong></p><p>Combination Therapy</p><p><em>&nbsp;</em></p><p><em>CLL14</em></p><p>CLL14 (BO25323) was a randomized (1:1), multicenter, open label, actively controlled, phase 3 trial (NCT02242942) that evaluated the efficacy and safety of VENCLEXTA in combination with obinutuzumab (VEN+G) versus obinutuzumab in combination with chlorambucil (GClb) for patients with previously untreated CLL with coexisting medical conditions (total Cumulative Illness Rating Scale [CIRS] score &gt; 6 or CLcr &lt; 70 mL/min). The trial required hepatic transaminases and total bilirubin &le;2 times upper limit of normal and excluded patients with Richter&rsquo;s transformation or any individual organ/system impairment score of 4 by CIRS except eye, ear, nose, and throat organ system.</p><p>All patients received obinutuzumab at 1000 mg on Day 1 (the first dose could be split as 100 mg and 900 mg on Days 1 and 2), and on Days 8 and 15 of Cycle 1, and on Day 1 of each subsequent cycle, for a total of 6 cycles. Patients in the VEN+G arm began the 5-week VENCLEXTA ramp-up schedule on Day 22 of Cycle 1, and received VENCLEXTA 400 mg once daily from Cycle 3 Day 1 until the last day of Cycle 12. Patients randomized to the GClb arm received 0.5 mg/kg oral chlorambucil on Day 1 and Day 15 of Cycles 1 to 12. Each cycle was 28 days.</p><p>A total of 432 patients were randomized, 216 to each study arm. Baseline demographic and disease characteristics were similar between the study arms. The median age was 72 years (range: 41 to 89 years), 89% were white, 67% were male; 36% and 43% were Binet stage B and C, respectively, and 88% had Eastern Cooperative Oncology Group (ECOG) performance status &lt;2. The median CIRS score was 8.0 (range: 0 to 28) and 58% of patients had CLcr &lt;70 mL/min. A 17p deletion was detected in 8% of patients, TP53 mutations in 7%, 11q deletion in 19%, and unmutated IgVH in 57%.</p><p>The major efficacy outcome was progression-free survival (PFS) as assessed by an Independent Review Committee (IRC). The median duration of follow-up for PFS was 28 months (range: 0.1 to 36 months).</p><p>Efficacy results for CLL14 are shown in Table 17. The Kaplan-Meier curve for PFS is shown in Figure 1.</p><p>Table 17. Efficacy Results in CLL14</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Endpoint</p></td><td><p>VENCLEXTA +<br />Obinutuzumab<br />(N = 216)</p></td><td><p>Obinutuzumab +<br />Chlorambucil<br />(N = 216)</p></td></tr><tr><td colspan="3"><p>Progression-free survivala</p></td></tr><tr><td><p>Number of events, n (%)</p></td><td><p>29 (13)</p></td><td><p>79 (37)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;Disease progression</p></td><td><p>14 (6)</p></td><td><p>71 (33)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;Death</p></td><td><p>15 (7)</p></td><td><p>8 (4)</p></td></tr><tr><td><p>Median, months</p></td><td><p>Not Reached</p></td><td><p>Not Reached</p></td></tr><tr><td><p>HR (95% CI)b</p></td><td colspan="2"><p>0.33 (0.22, 0.51)</p></td></tr><tr><td><p>p-valueb</p></td><td colspan="2"><p>&lt; 0.0001</p></td></tr><tr><td colspan="3"><p>Response ratec, n (%)</p></td></tr><tr><td><p>ORRd</p></td><td><p>183 (85)</p></td><td><p>154 (71)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;95% CI</p></td><td><p>(79, 89)</p></td><td><p>(65, 77)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;CR</p></td><td><p>100 (46)</p></td><td><p>47 (22)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;CR+CRid</p></td><td><p>107 (50)</p></td><td><p>50 (23)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;PR</p></td><td><p>76 (35)</p></td><td><p>104 (48)</p></td></tr><tr><td colspan="3"><p>CI = confidence interval; HR = hazard ratio; CR = complete remission; CRi = complete remission with incomplete marrow recovery; PR = partial remission; ORR = overall response rate (CR + CRi + PR).<br />aFrom randomization until earliest event of disease progression or death due to any cause. IRC-assessed; Kaplan-Meier estimate.<br />bHR estimate is based on Cox-proportional hazards model stratified by Binet Stage and geographic region; p-value based on log rank test stratified by the same factors.<br />cPer 2008 International Workshop for Chronic Lymphocytic Leukemia (IWCLL) guidelines.<br />dp-values based on Cochran-Mantel-Haenszel test; p=0.0007 for ORR; p &lt;0.0001 for CR+CRi.</p></td></tr></tbody></table><p><img alt="" width="567" height="294" src="data:image/png;base64,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" /></p><p>&nbsp;At the time of analysis, median overall survival (OS) had not been reached, with fewer than 10% of patients experiencing an event. The median duration of follow-up for OS was 28 months.</p><p>Minimal residual disease (MRD) was evaluated using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The definition of negative status was less than one CLL cell per 104 leukocytes. Rates of MRD negativity 3 months after the completion of treatment regardless of response and in patients who achieved CR are shown in Table 18. At this assessment, 134 patients in the VEN+G arm who were MRD negative in peripheral blood had matched bone marrow specimens; of these, 122 patients (91%) were MRD negative in both peripheral blood and bone marrow.</p><p>Table 18. Minimal Residual Disease Negativity Rates Three Months After the Completion of Treatment in CLL14</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td><td><p>VENCLEXTA +<br />Obinutuzumab</p></td><td><p>Obinutuzumab +<br />Chlorambucil</p></td></tr><tr><td colspan="3"><p>MRD negativity rate (ITT population)</p></td></tr><tr><td><p>N</p></td><td><p>216</p></td><td><p>216</p></td></tr><tr><td><p>Bone marrow, n (%)</p></td><td><p>123 (57)</p></td><td><p>37 (17)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;95% CI</p></td><td><p>(50, 64)</p></td><td><p>(12, 23)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;p-valuea</p></td><td colspan="2"><p>&lt;0.0001</p></td></tr><tr><td><p>Peripheral blood, n (%)</p></td><td><p>163 (76)</p></td><td><p>76 (35)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;95% CI</p></td><td><p>(69, 81)</p></td><td><p>(29, 42)</p></td></tr><tr><td><p>p-valuea</p></td><td colspan="2"><p>&lt;0.0001</p></td></tr><tr><td colspan="3"><p>MRD negativity rate in patients with CR</p></td></tr><tr><td><p>N</p></td><td><p>100</p></td><td><p>47</p></td></tr><tr><td><p>Bone marrow, n (%)</p></td><td><p>69 (69)</p></td><td><p>21 (45)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;95% CI</p></td><td><p>(59, 78)</p></td><td><p>(30, 60)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;p-valuea</p></td><td colspan="2"><p>0.0048</p></td></tr><tr><td><p>Peripheral blood, n (%)</p></td><td><p>87 (87)</p></td><td><p>29 (62)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;95% CI</p></td><td><p>(79, 93)</p></td><td><p>(46, 75)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;p-valuea</p></td><td colspan="2"><p>0.0005</p></td></tr><tr><td colspan="3"><p>CI = confidence interval; CR = complete remission.<br />ap-value based on Chi-square test</p></td></tr></tbody></table><p>Twelve months after the completion of treatment, MRD negativity rates in peripheral blood were 58% (126/216) in patients treated with VEN+G and 9% (20/216) in patients treated with GClb.</p><p><strong>&nbsp;</strong></p><p><em>MURANO</em></p><p>MURANO was a randomized (1:1), multicenter, open label study (NCT02005471) that evaluated the efficacy and safety of VENCLEXTA in combination with rituximab (VEN+R) versus bendamustine in combination with rituximab (B+R) in patients with CLL who had received at least one line of prior therapy. Patients in the VEN+R arm completed the 5-week ramp-up schedule and received VENCLEXTA 400 mg once daily for 24 months from Cycle 1 Day 1 of rituximab in the absence of disease progression or unacceptable toxicity. Rituximab was initiated intravenously after the 5-week dose ramp-up at 375 mg/m2 on Day 1 of Cycle 1 and 500 mg/m2 on Day 1 of Cycles 2-6. Each cycle was 28 days. Patients randomized to B+R received bendamustine at 70 mg/m2 on Days 1 and 2 for 6 cycles (28-day cycle) and rituximab at the above described dose and schedule.</p><p><strong>&nbsp;</strong></p><p>A total of 389 patients were randomized: 194 to the VEN+R arm and 195 to the B+R arm.</p><p>Baseline demographic and disease characteristics were similar between the VEN+R and B+R arms. The median age was 65 years (range: 22-85 years), 97% were white, 74% were male, and 99% had ECOG performance status &lt;2. Median prior lines of therapy was 1 (range: 1-5); 59% had received 1 prior therapy, 26% had received 2 prior therapies, and 16% had received 3 or more prior therapies. Prior therapies included alkylating agents (94%), anti-CD20 antibodies (77%), B-cell receptor pathway inhibitors (2%), and prior purine analogs (81%, including fludarabine/cyclophosphamide/rituximab in 55%). A 17p deletion was detected in 24% of patients, <em>TP53 </em>mutations in 25%, 11q deletion in 32%, and unmutated <em>IgVH </em>in 63%.</p><p>&nbsp;</p><p>&nbsp;Efficacy was based on progression-free survival (PFS) as assessed by an Independent Review Committee (IRC). The median follow-up for PFS was 23.4 months (range: 0 to 37.4+ months).</p><p>&nbsp;</p><p>Efficacy results for MURANO are shown in Table 19. The Kaplan-Meier curve for PFS is shown</p><p>in Figure 2.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>Table 19. IRC-Assessed Efficacy Results in MURANO</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>VENCLEXTA + Rituximab </strong></p><p><strong>(N = 194)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;Bendamustine + Rituximab </strong></p><p><strong>(N = 195)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-free survival<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>35 (18)</p></td><td style="vertical-align:top"><p>106 (54)</p></td></tr><tr><td style="vertical-align:top"><p>Disease progression, n</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>91</p></td></tr><tr><td style="vertical-align:top"><p>Death events, n</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>Not Reached</p></td><td style="vertical-align:top"><p>18.1 (15.8, 22.3)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.19 (0.13, 0.28)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response rate<sup>c</sup>, n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR</p></td><td style="vertical-align:top"><p>179 (92)</p></td><td style="vertical-align:top"><p>141 (72)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(88, 96)</p></td><td style="vertical-align:top"><p>(65, 78)</p></td></tr><tr><td style="vertical-align:top"><p>CR+CRi</p></td><td style="vertical-align:top"><p>16 (8)</p></td><td style="vertical-align:top"><p>7 (4)</p></td></tr><tr><td style="vertical-align:top"><p>nPR</p></td><td style="vertical-align:top"><p>3 (2)</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>160 (82)</p></td><td style="vertical-align:top"><p>133 (68)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI = confidence interval; HR = hazard ratio; CR = complete remission; CRi = complete remission with incomplete marrow recovery; nPR = nodular partial remission; PR = partial remission; ORR = overall response rate (CR + CRi + nPR + PR).</p><p><sup>a</sup>Kaplan-Meier estimate.</p><p><sup>b</sup>HR estimate is based on Cox-proportional hazards model stratified by 17p deletion, risk status, and geographic region; p-value based on log-rank test stratified by the same factors.</p><p><sup>c</sup>Per 2008 International Workshop for Chronic Lymphocytic Leukemia (IWCLL) guidelines.</p><p><img alt="" width="678" height="406" src="data:image/png;base64,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" /></p><p>At the time of analysis, median overall survival had not been reached in either arm after a median follow-up of 22.9 months.</p><p>Minimal residual disease (MRD) was evaluated using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The definition of negative status was less than one CLL cell per 104 leukocytes. At 3 months after the last dose of rituximab, the MRD negativity rate in peripheral blood in patients who achieved PR or better was 53% (103/194) in the VEN+R arm and 12% (23/195) in the B+R arm.&nbsp; The MRD-negative CR/CRi rate at this timepoint was 3% (6/194) in the VEN+R arm and 2% (3/195) in the B+R arm.</p><p><strong>&nbsp;</strong></p><p><strong>Monotherapy</strong></p><p>The efficacy of VENCLEXTA monotherapy in previously-treated CLL or SLL is based on three single-arm studies.</p><p><em>&nbsp;</em></p><p><em>Study M13-982</em></p><p>The efficacy of VENCLEXTA was established in study M13-982 (NCT01889186), an openlabel, single-arm, multicenter clinical trial of 106 patients with CLL with 17p deletion who had received at least one prior therapy. In the study, 17p deletion was confirmed in peripheral blood specimens from patients using Vysis CLL FISH Probe Kit, which is FDA approved for selection of patients for VENCLEXTA treatment. Patients received VENCLEXTA via a weekly ramp-up schedule starting at 20 mg and ramping to 50 mg, 100 mg, 200 mg and finally 400 mg once</p><p>daily. Patients continued to receive 400 mg of VENCLEXTA orally once daily until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Efficacy was based on overall response rate (ORR) as assessed by an Independent Review</p><p>Committee (IRC).</p><p>&nbsp;</p><p>Table 20 summarizes the baseline demographic and disease characteristics of the study</p><p>population.</p><p>Table 20. Baseline Patient Characteristics in Study M13-982</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:90%"><tbody><tr><td><p><strong>Characteristic</strong></p></td><td><p><strong>N = 106</strong></p></td></tr><tr><td><p>Age, years; median (range)</p></td><td><p>67 (37-83)</p></td></tr><tr><td><p>White; %</p></td><td><p>97</p></td></tr><tr><td><p>Male; %</p></td><td><p>65</p></td></tr><tr><td><p>ECOG performance status; %<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p></td><td><p>&nbsp;</p><p>40<br />52<br />8</p></td></tr><tr><td><p>Tumor burden; %<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absolute lymphocyte count &ge;25 x 10<sup>9</sup>/L<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One or more nodes &ge;5 cm</p></td><td><p>&nbsp;</p><p>50<br />53</p></td></tr><tr><td><p>Number of prior therapies; median (range)</p></td><td><p>2.5 (1-10)</p></td></tr><tr><td><p>Time since diagnosis, years; median (range)<sup>a</sup></p></td><td><p>6.6 (0.1-32.1)</p></td></tr><tr><td colspan="2"><p><sup>a</sup>N=105.</p></td></tr></tbody></table><p>&nbsp;</p><p>The median time on treatment at the time of evaluation was 12.1 months (range: 0 to 21.5 months). Efficacy results are shown in Table 19</p><p>&nbsp;</p><p>Table 21. Efficacy Results per IRC for Patients with Previously Treated CLL with 17p</p><p>Deletion in Study M13-982</p><table border="1" cellspacing="0" cellpadding="0" style="width:90%"><tbody><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>VENCLEXTA<br />N=106</strong></p></td></tr><tr><td><p>ORR, n (%)<sup>a</sup><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(95% CI)</p></td><td><p>85 (80)<br />(71, 87)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CR + CRi, n (%)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CR, n (%)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CRi, n (%)</p></td><td><p>8 (8)<br />6 (6)<br />2 (2)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nPR, n (%)</p></td><td><p>3 (3)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PR, n (%)</p></td><td><p>74 (70)</p></td></tr><tr><td colspan="2"><p>CI = confidence interval; CR = complete remission; CRi = complete remission with incomplete marrow recovery; IRC = independent review committee; nPR = nodular partial remission; ORR = overall response rate (CR + CRi + nPR + PR); PR = partial remission.</p><p><sup>a</sup>Per 2008 IWCLL guidelines.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>The median time to first response was 0.8 months (range: 0.1 to 8.1 months).</p><p>Based on a later data cutoff date and investigator-assessed efficacy, the duration of response (DOR) ranged from 2.9 to 32.8+ months. The median DOR has not been reached with median follow-up of 22 months.</p><p>MRD was evaluated in peripheral blood and bone marrow for patients who achieved CR or CRi, following treatment with VENCLEXTA. Three percent (3/106) achieved MRD negativity in the peripheral blood and bone marrow (less than one CLL cell per 10<sup>4</sup> leukocytes).</p><p>&nbsp;</p><p><em>Study M12-175</em></p><p>Study M12-175 (NCT01328626) was a multicenter, open-label trial that enrolled previously treated patients with CLL or SLL, including those with 17p deletion. Efficacy was evaluated in 67 patients (59 with CLL, 8 with SLL) who had received a 400 mg daily dose of VENCLEXTA.Patients continued this dose until disease progression or unacceptable toxicity. The median duration of treatment at the time of evaluation was 22.1 months (range: 0.5 to 50.1 months).</p><p>The median age was 66 years (range: 42 to 84 years), 78% were male and 87% were white. The median number of prior treatments was 3 (range: 1 to 11). At baseline, 67% of patients had one or more nodes &ge;5 cm, 30% of patients had ALC &ge;25 x 109/L, 33% had documented unmutated <em>IgVH</em>, and 21% had documented 17p deletion.</p><p>Efficacy in CLL was evaluated according to 2008 IWCLL guidelines. As assessed by an IRC, the ORR was 71% (95% CI: 58%, 82%), CR + CRi rate was 7%, and PR rate was 64%. Based on investigator assessments, the ORR in patients with CLL was 80% (14% CR+ CRi, 66% PR + nPR). With an estimated median follow-up of 25.2 months, the DOR ranged from 2.3+ to 48.6+ months. Of the 47 responders, 83% had a DOR of at least 12 months.</p><p>&nbsp;</p><p>For the 8 patients with SLL, the investigator-assessed ORR was 100%.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Study M14-032</em></p><p>Study M14-032 (NCT02141282) was an open-label, multicenter, study that evaluated the efficacy of VENCLEXTA in patients with CLL who had been previously treated with and progressed on or after ibrutinib or idelalisib. Patients received a daily dose of 400 mg of VENCLEXTA following the ramp-up schedule. Patients continued to receive VENCLEXTA 400 mg once daily until disease progression or unacceptable toxicity. At the time of analysis, the median duration of treatment was 14.3 months (range: 0.1 to 31.4 months).</p><p>&nbsp;</p><p>Of the 127 patients treated (91 with prior ibrutinib, 36 with prior idelalisib), the median age was 66 years (range: 28 to 85 years), 70% were male and 92% were white. The median number of prior treatments was 4 (range: 1 to 15). At baseline, 41% of patients had one or more nodes &ge;5 cm, 31% had an absolute lymphocyte count &ge;25 x 109/L, 57% had documented unmutated IgVH, and 39% had documented 17p deletion.</p><p>Efficacy was based on 2008 IWCLL guidelines. Based on IRC assessment, the ORR was 70% (95% CI: 61%, 78%), with a CR + CRi rate of 1%, and PR rate of 69%.</p><p>Based on investigator assessment, the ORR was 65% (95% CI: 56%, 74%). The median DOR per investigator has not been reached with an estimated median follow-up of 14.6 months.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Acute Myeloid Leukemia</strong></p><p>VENCLEXTA was studied in two open-label non-randomized trials in patients with newlydiagnosed AML who were &ge;75 years of age, or had comorbidities that precluded the use of intensive induction chemotherapy based on at least one of the following criteria: baseline Eastern Cooperative Oncology Group (ECOG) performance status of 2-3, severe cardiac or pulmonary comorbidity, moderate hepatic impairment, or CLcr &lt;45 mL/min or other comorbidity. Efficacy was established based on the rate of complete remission (CR) and the duration of CR.</p><p>&nbsp;</p><p><strong>Study M14-358 </strong></p><p>VENCLEXTA was studied in a non-randomized, open-label clinical trial (NCT02203773) of</p><p>VENCLEXTA in combination with azacitidine (N=84) or decitabine (N=31) in patients with newly-diagnosed AML. Of those patients, 67 who received azacitidine combination and 13 who received decitabine combination were age 75 or older or had comorbidities that precluded the use of intensive induction chemotherapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients received VENCLEXTA via a daily ramp-up to a final 400 mg once daily dose. During the ramp-up, patients received TLS prophylaxis and were hospitalized for monitoring. Azacitidine at 75 mg/m2 was administered either intravenously or subcutaneously on Days 1-7 of each 28-day cycle beginning on Cycle 1 Day 1. Decitabine at 20 mg/m2was administered intravenously on Days 1-5 of each 28-day cycle beginning on Cycle 1 Day 1. Patients continued to receive treatment cycles until disease progression or unacceptable toxicity. Azacitidine dose reduction was implemented in the clinical trial for management of hematologic toxicity, see azacitidine full prescribing information. Dose reductions for decitabine were not implemented in the clinical trial.</p><p>&nbsp;</p><p>Table 22 summarizes the baseline demographic and disease characteristics of the study population.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 22. Baseline Patient Characteristics for Patients with AML Treated with VENCLEXTA in Combination with Azacitidine or Decitabine</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Characteristic</strong></p></td><td><p><strong>VENCLEXTA in Combination with Azacitidine</strong></p><p><strong>N = 67</strong></p></td><td style="vertical-align:top"><p><strong>VENCLEXTA in Combination with Decitabine</strong></p><p><strong>N = 13</strong></p></td></tr><tr><td><p>Age, years; median (range)</p></td><td><p>76 (61-90)</p></td><td style="vertical-align:top"><p>75 (68-86)</p></td></tr><tr><td><p>Race</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; White; %</p></td><td><p>87</p></td><td style="vertical-align:top"><p>77</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Black or African American; %</p></td><td><p>4.5</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Asian; %</p></td><td><p>1.5</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Native Hawaiian or Pacific Islander; %</p></td><td><p>1.5</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; American Indian/Alaskan Native; %</p></td><td><p>0</p></td><td style="vertical-align:top"><p>7.7</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Unreported/Other; %</p></td><td><p>6.0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td><p>Male; %</p></td><td><p>60</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td><p>ECOG performance status; %</p><p>&nbsp;&nbsp;&nbsp;&nbsp; 0-1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3</p></td><td><p>&nbsp;</p><p>64</p><p>33</p><p>3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>92</p><p>8</p><p>0</p></td></tr><tr><td><p>Disease history; %<br />&nbsp;&nbsp;&nbsp;&nbsp; <em>De Novo</em> AML</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Secondary AML</p></td><td><p>&nbsp;</p><p>73</p><p>27</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>85</p><p>15</p></td></tr><tr><td colspan="3"><p>Mutation analyses detected<sup>a</sup>; %&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <em>TP53</em></p></td><td><p>21</p></td><td><p>31</p></td></tr><tr><td><p><em>&nbsp;&nbsp;&nbsp;&nbsp; IDH1 or IDH2</em></p></td><td><p>27</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <em>FLT-3</em></p></td><td><p>16</p></td><td><p>23</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <em>NPM1 </em></p></td><td><p>19</p></td><td><p>15</p></td></tr><tr><td><p>Cytogenetic risk detected<sup>b,c</sup>; %</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Intermediate</p></td><td><p>64</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Poor</p></td><td><p>34</p></td><td style="vertical-align:top"><p>62</p></td></tr><tr><td><p>Baseline comorbidities<sup>d</sup>, %</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Severe cardiac disease</p></td><td><p>4.5</p></td><td style="vertical-align:top"><p>7.7</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Severe pulmonary disease</p></td><td><p>1.5</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Moderate hepatic impairment</p></td><td><p>9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Creatinine clearance &lt;45 mL/min</p></td><td><p>13</p></td><td style="vertical-align:top"><p>7.7</p></td></tr><tr><td colspan="3"><p><sup>a</sup>Includes 6 patients with insufficient sample for analysis in the azacitidine group and 4 in the decitabine group.</p><p><sup>b</sup>As defined by the National Comprehensive Cancer Network (NCCN) risk categorization v2014.</p><p><sup>c</sup>No mitosis in 1 patient in azacitidine group (excluded favorable risk by Fluorescence in situ Hybridization [FISH] analysis).</p><p><sup>d</sup>Patients may have had more than one comorbidity.&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The efficacy results are shown in Table 23.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Table 23. Efficacy Results for Patients with Newly-Diagnosed AML Treated with</p><p>VENCLEXTA in Combination with Azacitidine or Decitabine</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Efficacy Outcomes</strong></p></td><td><p><strong>VENCLEXTA in Combination with Azacitidine</strong><br /><strong>N = 67</strong></p></td><td style="vertical-align:top"><p><strong>VENCLEXTA in Combination with Decitabine</strong></p><p><strong>N = 13</strong></p></td></tr><tr><td><p>CR, n (%)<br />&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p><p>&nbsp;</p></td><td><p>25 (37)</p><p>(26, 50)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>7 (54)</p><p>(25, 81)</p><p>&nbsp;</p></td></tr><tr><td><p>CRh, n (%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td><p>16 (24)</p><p>(14, 36)</p></td><td style="vertical-align:top"><p>1 (7.7)</p><p>(0.2, 36)</p></td></tr><tr><td colspan="3"><p>CI = confidence interval; NR = not reached.</p><p>CR (complete remission) was defined as absolute neutrophil count &gt;1,000/microliter, platelets &gt;100,000/microliter, red blood cell transfusion independence, and bone marrow with &lt;5% blasts. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.&nbsp;</p><p>CRh (complete remission with partial hematological recovery) was defined as &lt;5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt;50,000/microliter and ANC &gt;500/microliter).</p></td></tr></tbody></table><p>&nbsp;</p><p>The median follow-up was 7.9 months (range: 0.4 to 36 months) for VENCLEXTA in combination with azacitidine. At the time of analysis, for patients who achieved a CR, the median observed time in remission was 5.5 months (range: 0.4 to 30 months). The observed time in remission is the time from the start of CR to the time of data cut-off date or relapse from CR.</p><p>The median follow-up was 11 months (range: 0.7 to 21 months) for VENCLEXTA in combination with decitabine. At the time of analysis, for patients who achieved a CR, the median observed time in remission was 4.7 months (range: 1.0 to 18 months). The observed time in remission is the time from the start of CR to the time of data cut-off date or relapse from CR.</p><p>Median time to first CR or CRh for patients treated with VENCLEXTA in combination with azacitidine was 1.0 month (range: 0.7 to 8.9 months).</p><p>Median time to first CR or CRh for patients treated with VENCLEXTA in combination with decitabine was 1.9 months (range: 0.8 to 4.2 months).</p><p>Of patients treated with VENCLEXTA in combination with azacitidine, 7.5% (5/67) subsequently received stem cell transplant.</p><p>&nbsp;</p><p>The study enrolled 35 additional patients (age range: 65 to 74 years) who did not have known comorbidities that preclude the use of intensive induction chemotherapy and were treated with VENCLEXTA in combination with azacitidine (N=17) or decitabine (N=18).</p><p>&nbsp;</p><p>For the 17 patients treated with VENCLEXTA in combination with azacitidine, the CR rate was 35% (95% CI: 14%, 62%). The CRh rate was 41% (95% CI: 18%, 67%). Seven (41%) patients subsequently received stem cell transplant.</p><p>For the 18 patients treated with VENCLEXTA in combination with decitabine, the CR rate was 56% (95% CI: 31%, 79%). The CRh rate was 22% (95% CI: 6.4%, 48%). Three (17%) patients subsequently received stem cell transplant.</p><p>&nbsp;</p><p>Study M14-387</p><p>VENCLEXTA was studied in a non-randomized, open-label clinical trial (NCT02287233) of VENCLEXTA in combination with low dose cytarabine (N=82) in patients with newly diagnosed AML, including patients with previous exposure to a hypomethylating agent for an antecedent hematologic disorder. Of those patients, 61 were age 75 or older or had comorbidities that precluded the use of intensive induction chemotherapy based on at least one of the criterion: baseline Eastern Cooperative Oncology Group (ECOG) performance status of 2-3, severe cardiac or pulmonary comorbidity, moderate hepatic impairment, or CLcr &ge;30 to &lt;45 mL/min or other comorbidity.</p><p>&nbsp;</p><p>Patients initiated VENCLEXTA via daily ramp-up to a final 600 mg once daily dose. During the ramp-up, patients received TLS prophylaxis and<em> </em>were hospitalized for monitoring. Cytarabine at a dose of 20 mg/m2 was administered<em> </em>subcutaneously once daily on Days 1-10 of each 28-day cycle beginning on Cycle 1 Day 1.</p><p>Patients continued to receive treatment cycles until disease progression or unacceptable toxicity.</p><p>Dose reduction for low-dose cytarabine was not implemented in the clinical trial.</p><p>&nbsp;</p><p>Table 24 summarizes the baseline demographic and disease characteristics of the study population.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 24. Baseline Patient Characteristics for Patients with AML Treated with VENCLEXTA in Combination with Low-Dose Cytarabine</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td><p><strong>Characteristic</strong></p></td><td><p><strong>VENCLEXTA in Combination with Low-Dose Cytarabine </strong></p><p><strong>N = 61</strong></p></td></tr><tr><td><p>Age, years; median (range)</p></td><td><p>76 (63-90)</p></td></tr><tr><td><p>Race</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; White; %</p></td><td><p>92</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Black or African American; %</p></td><td><p>1.6</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Asian; %</p></td><td><p>1.6</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Unreported; %</p></td><td><p>4.9</p></td></tr><tr><td><p>Male; %</p></td><td><p>74</p></td></tr><tr><td><p>ECOG performance status; %<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0-1<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3</p></td><td><p>&nbsp;</p><p>66</p><p>33</p><p>1.6</p></td></tr><tr><td><p>Disease history, %<br />&nbsp;&nbsp;&nbsp;&nbsp; <em>De novo</em> AML</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Secondary AML</p></td><td><p>&nbsp;</p><p>54</p><p>46</p></td></tr><tr><td><p>Mutation analyses detected; %</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <em>TP53&nbsp; </em></p></td><td><p>8</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <em>IDH1 or IDH2 </em></p></td><td><p>23</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <em>FLT-3 </em></p></td><td><p>21</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <em>NPM1 </em></p></td><td><p>9.8</p></td></tr><tr><td><p>Cytogenetic risk detected<sup>b</sup>; %</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Intermediate</p></td><td><p>59</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Poor</p></td><td><p>34</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; No mitoses</p></td><td><p>6.6</p></td></tr><tr><td><p>Baseline comorbidities<sup>c</sup>, %</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Severe cardiac disease</p></td><td><p>9.8</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Moderate hepatic impairment</p></td><td><p>4.9</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; Creatinine clearance &ge;30 or &lt;45 mL/min</p></td><td><p>3.3</p></td></tr><tr><td colspan="2"><p><sup>a</sup>Includes 7 patients with insufficient sample for analysis.</p><p><sup>b</sup>As defined by the National Comprehensive Cancer Network (NCCN) risk categorization v2014</p><p><sup>c</sup>Patients may have had more than one comorbidity.&nbsp;</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Efficacy results are shown in Table 25.</p><p><strong>&nbsp;</strong></p><p>Table 25. Efficacy Results for Patients with Newly-Diagnosed AML Treated with VENCLEXTA in Combination with Low-Dose Cytarabine</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td><p><strong>Efficacy Outcomes</strong></p></td><td><p><strong>VENCLEXTA in Combination&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with Low-Dose Cytarabine</strong><br /><strong>N = 61</strong></p></td></tr><tr><td><p>CR, n (%)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p><p>&nbsp;</p></td><td><p>13 (21)</p><p>(12, 34)</p><p>&nbsp;</p></td></tr><tr><td><p>CRh, n (%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td><p>13 (21)</p><p>(12, 34)</p></td></tr><tr><td colspan="2"><p>CI = confidence interval; NR = not reached.</p><p>CR (complete remission) was defined as absolute neutrophil count &gt;1,000/microliter, platelets &gt;100,000/microliter, red blood cell transfusion independence, and bone marrow with &lt;5% blasts. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.</p><p>CRh (complete remission with partial hematological recovery) was defined as &lt;5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt;50,000/microliter and ANC &gt;500/microliter).</p></td></tr></tbody></table><p>&nbsp;</p><p>The median follow-up was 6.5 months (range: 0.3 to 34 months). At the time of analysis, for patients who achieved a CR, the median observed time in remission was 6.0 months (range: 0.03 to 25 months). The observed time in remission is the time from the start of CR to the time of data cut-off date or relapse from CR.</p><p>Median time to first CR or CRh for patients treated with VENCLEXTA in combination with low-dose cytarabine was 1.0 month (range: 0.8 to 9.4 months).</p><p>&nbsp;</p><p>The study enrolled 21 additional patients (age range: 67 to 74 years) who did not have known comorbidities that preclude the use of intensive induction chemotherapy and were treated with VENCLEXTA in combination with low-dose cytarabine. The CR rate was 33% (95% CI:15%, 57%). The CRh rate was 24% (95% CI: 8.2%, 47%). One patient (4.8%) subsequently received stem cell transplant.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venclexta VENCLEXTA 10 mg film-coated tablets:</p><p>Copovidone</p><p>Colloidal anhydrous silica</p><p>Polysorbate 80</p><p>Sodium stearyl fumarate</p><p>Calcium phosphate dibasic</p><p>Iron oxide yellow</p><p>Polyvinyl alcohol</p><p>Titanium dioxide</p><p>Macrogol</p><p>Talc</p><p>&nbsp;</p><p>Venclexta VENCLEXTA 50 mg film-coated tablets:</p><p>Copovidone</p><p>Colloidal anhydrous silica</p><p>Polysorbate 80</p><p>Sodium stearyl fumarate</p><p>Calcium phosphate dibasic</p><p>Iron oxide yellow</p><p>Iron oxide red</p><p>Iron oxide black</p><p>Polyvinyl alcohol</p><p>Titanium dioxide</p><p>Macrogol</p><p>Talc</p><p>&nbsp;</p><p>Venclexta VENCLEXTA 100 mg film-coated tablets:</p><p>Copovidone</p><p>Colloidal anhydrous silica</p><p>Polysorbate 80</p><p>Sodium stearyl fumarate</p><p>Calcium phosphate dibasic</p><p>Iron oxide yellow</p><p>Polyvinyl alcohol</p><p>Titanium dioxide</p><p>Macrogol</p><p>Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
3 years for Venclexta 100 mg

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Don&rsquo;t store above 30⁰ C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VENCLEXTA is dispensed as follows:</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Packaging Presentation</strong></p></td><td style="vertical-align:top"><p><strong>Number of Tablets</strong></p></td></tr><tr><td style="vertical-align:top"><p>CLL/SLL Starting Pac k</p></td><td style="vertical-align:top"><p>Each pack contains four weekly</p><p>wallet blister packs:</p><p>&bull; Week 1 (14 x 10 mg tablets)</p><p>&bull; Week 2 (7 x 50 mg tablets)</p><p>&bull; Week 3 (7 x 100 mg tablets)</p><p>&bull; Week 4 (14 x 100 mg tablets)</p></td></tr><tr><td style="vertical-align:top"><p>Wallet containing 10 mg tablets</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>14 x 10 mg tablets</p></td></tr><tr><td style="vertical-align:top"><p>Wallet containing 50 mg tablets</p></td><td style="vertical-align:top"><p>7 x 50 mg tablets</p></td></tr><tr><td style="vertical-align:top"><p>Unit dose blister containing 10 mg tablets</p></td><td style="vertical-align:top"><p>2 x 10 mg tablets</p></td></tr><tr><td style="vertical-align:top"><p>Unit dose blister containing 50 mg tablet</p></td><td style="vertical-align:top"><p>1 x 50 mg tablet</p></td></tr><tr><td style="vertical-align:top"><p>Unit dose blister containing 100 mg tablet</p></td><td style="vertical-align:top"><p>1 x 100 mg tablet</p></td></tr><tr><td style="vertical-align:top"><p>Bottle containing 100 mg tablets</p></td><td style="vertical-align:top"><p>120 x 100 mg tablets</p></td></tr></tbody></table><p>&nbsp;</p><p>VENCLEXTA 10 mg film-coated tablets are round, biconvex shaped, pale yellow debossed with &ldquo;V&rdquo; on one side and &ldquo;10&rdquo; on the other side.</p><p>VENCLEXTA 50 mg film-coated tablets are oblong, biconvex shaped, beige debossed with &ldquo;V&rdquo; on one side and &ldquo;50&rdquo; on the other side.</p><p>VENCLEXTA 100 mg film-coated tablets are oblong, biconvex shaped, pale yellow debossed with &ldquo;V&rdquo; on one side and &ldquo;100&rdquo; on the other side.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Inc North Chicago
IL 60064
Chicago
United States

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>